<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">NAR Cancer</journal-id><journal-id journal-id-type="iso-abbrev">NAR Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">4040</journal-id><journal-id journal-id-type="pmc-domain">narcan</journal-id><journal-id journal-id-type="publisher-id">narcancer</journal-id><journal-title-group><journal-title>NAR Cancer</journal-title></journal-title-group><issn pub-type="epub">2632-8674</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12754786</article-id><article-id pub-id-type="pmcid-ver">PMC12754786.1</article-id><article-id pub-id-type="pmcaid">12754786</article-id><article-id pub-id-type="pmcaiid">12754786</article-id><article-id pub-id-type="pmid">41480640</article-id><article-id pub-id-type="doi">10.1093/narcan/zcaf057</article-id><article-id pub-id-type="publisher-id">zcaf057</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Manipulating DNA repair and the DNA damage response to improve cancer therapy</subject><subj-group subj-group-type="category-toc-heading"><subject>DNA Damage Sensing and Repair</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/SCI00030</subject><subject>AcademicSubjects/SCI00980</subject><subject>AcademicSubjects/SCI01060</subject><subject>AcademicSubjects/SCI01140</subject><subject>AcademicSubjects/SCI01180</subject></subj-group></article-categories><title-group><article-title>Replication-associated base excision repair/single-strand break repair regulates PARG inhibitor response via the PRMT1/PRMT5/ATR axis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2241-1500</contrib-id><name name-style="western"><surname>Ibrahim</surname><given-names initials="M">Md</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation" degree-contribution="equal">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="equal">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="equal">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="equal">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources" degree-contribution="equal">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization" degree-contribution="equal">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="equal">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role><aff>
<institution>Department of Pharmacology &amp; Mitchell Cancer Institute, University of South Alabama</institution>, <addr-line>Mobile, AL 36604</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0474-7414</contrib-id><name name-style="western"><surname>Roos</surname><given-names initials="WP">Wynand P</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation" degree-contribution="supporting">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="supporting">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="lead">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources" degree-contribution="supporting">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation" degree-contribution="supporting">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization" degree-contribution="supporting">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="supporting">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role><aff>
<institution>Department of Pathology and Laboratory Medicine, Warren Alpert Medical School &amp; Legorreta Cancer Center, Brown University</institution>, <addr-line>Providence, RI 02912</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schwartz</surname><given-names initials="JC">Jacob C</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="supporting">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role><aff>
<institution>Department of Pathology and Laboratory Medicine, Warren Alpert Medical School &amp; Legorreta Cancer Center, Brown University</institution>, <addr-line>Providence, RI 02912</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khan</surname><given-names initials="MM">Md Maruf</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="supporting">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation" degree-contribution="supporting">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role><aff>
<institution>Department of Pathology and Laboratory Medicine, Warren Alpert Medical School &amp; Legorreta Cancer Center, Brown University</institution>, <addr-line>Providence, RI 02912</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Al-Rahahleh</surname><given-names initials="RQ">Rasha Q</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role><aff>
<institution>Department of Pathology and Laboratory Medicine, Warren Alpert Medical School &amp; Legorreta Cancer Center, Brown University</institution>, <addr-line>Providence, RI 02912</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beers</surname><given-names initials="LA">Libby A</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="supporting">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role><aff>
<institution>Department of Pathology and Laboratory Medicine, Warren Alpert Medical School &amp; Legorreta Cancer Center, Brown University</institution>, <addr-line>Providence, RI 02912</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pearson</surname><given-names initials="CR">Charlotte R</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="supporting">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role><aff>
<institution>Department of Pathology and Laboratory Medicine, Warren Alpert Medical School &amp; Legorreta Cancer Center, Brown University</institution>, <addr-line>Providence, RI 02912</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Langham</surname><given-names initials="KT">Kahrie T</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="supporting">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role><aff>
<institution>Department of Pathology and Laboratory Medicine, Warren Alpert Medical School &amp; Legorreta Cancer Center, Brown University</institution>, <addr-line>Providence, RI 02912</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boyang</surname><given-names initials="L">Louis</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="supporting">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role><aff>
<institution>Department of Pathology and Laboratory Medicine, Warren Alpert Medical School &amp; Legorreta Cancer Center, Brown University</institution>, <addr-line>Providence, RI 02912</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Clark</surname><given-names initials="J">Jennifer</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="supporting">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources" degree-contribution="supporting">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role><aff>
<institution>Department of Pharmacology &amp; Mitchell Cancer Institute, University of South Alabama</institution>, <addr-line>Mobile, AL 36604</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hayat</surname><given-names initials="F">Faisal</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources" degree-contribution="supporting">Resources</role><aff>
<institution>Department of Pharmacology &amp; Mitchell Cancer Institute, University of South Alabama</institution>, <addr-line>Mobile, AL 36604</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fang</surname><given-names initials="Q">Qingming</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources" degree-contribution="supporting">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role><aff>
<institution>Department of Pharmacology &amp; Mitchell Cancer Institute, University of South Alabama</institution>, <addr-line>Mobile, AL 36604</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Koczor</surname><given-names initials="CA">Christopher A</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources" degree-contribution="supporting">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role><aff>
<institution>Department of Pharmacology &amp; Mitchell Cancer Institute, University of South Alabama</institution>, <addr-line>Mobile, AL 36604</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Migaud</surname><given-names initials="ME">Marie E</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources" degree-contribution="supporting">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="supporting">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role><aff>
<institution>Department of Pharmacology &amp; Mitchell Cancer Institute, University of South Alabama</institution>, <addr-line>Mobile, AL 36604</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7385-3563</contrib-id><name name-style="western"><surname>Sobol</surname><given-names initials="RW">Robert W</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="lead">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation" degree-contribution="equal">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="equal">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition" degree-contribution="equal">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="equal">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="lead">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="lead">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation" degree-contribution="equal">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization" degree-contribution="equal">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="equal">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="lead">Writing - review &amp; editing</role><aff>
<institution>Department of Pharmacology &amp; Mitchell Cancer Institute, University of South Alabama</institution>, <addr-line>Mobile, AL 36604</addr-line>, <country country="US">United States</country></aff><aff>
<institution>Department of Pathology and Laboratory Medicine, Warren Alpert Medical School &amp; Legorreta Cancer Center, Brown University</institution>, <addr-line>Providence, RI 02912</addr-line>, <country country="US">United States</country></aff><xref rid="COR1" ref-type="corresp"/></contrib></contrib-group><author-notes><corresp id="COR1">To whom correspondence should be addressed. Email: <email>robert_sobol@brown.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-12-31"><day>31</day><month>12</month><year>2025</year></pub-date><volume>7</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">498459</issue-id><elocation-id>zcaf057</elocation-id><history><date date-type="received"><day>19</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>10</day><month>12</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-02 11:25:13.197"><day>02</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="zcaf057.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zcaf057.pdf"/><abstract><title>Abstract</title><p>Poly(ADP-ribose) polymerases 1 and 2 (PARP1/PARP2), and poly(ADP-ribose) glycohydrolase (PARG), modulate the level of poly(ADP-ribose) (PAR), a post-translational protein modification, in response to DNA damage or replication stress. Here, we find that replication-dependent and PARP1/PARP2-mediated PARylation recruits the base excision repair (BER)/single-strand break repair (SSBR) scaffold protein XRCC1 and the associated factors DNA polymerase &#946; (POLB), aprataxin (APTX), and DNA ligase isoform 3 (LIG3). Further, these BER/SSBR proteins promote resistance to inhibitors of PARP1/PARP2 and PARG, as loss of these proteins sensitizes glioblastoma and ovarian cancer cells to each. In addition, depletion of these replication-associated BER/SSBR factors leads to enhanced PAR levels and PARG inhibitor-induced activation of the ATR/CHK1 S-phase checkpoint kinases. Both PARG inhibition and ATR inhibition lead to elevated ATM- and DNA-PK-dependent KAP1 phosphorylation. In turn, inhibition of either ATR or CHK1 enhances the cellular response to PARG inhibitors. Finally, inhibition of the ATR regulators PRMT1 or PRMT5 synergizes with PARG inhibition, implicating replication-associated BER/SSBR and PARylation in the activation of the PRMT1/PRMT5/ATR axis. This study highlights the role of BER/SSBR in protecting the cell during S-phase to suppress PARylation-induced checkpoint activation, which may suggest a potential intervention strategy for PARG inhibitor-resistant tumors.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<fig position="float" id="ga1" orientation="portrait"><label>Graphical Abstract</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="zcaf057figgra1.jpg"/></fig>
</p></abstract><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>NIH</institution><institution-id institution-id-type="DOI">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>ES029518</award-id><award-id>ES028949</award-id><award-id>CA238061</award-id><award-id>CA236911</award-id><award-id>AG069740</award-id><award-id>ES032522</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>NSF</institution><institution-id institution-id-type="DOI">10.13039/100000001</institution-id></institution-wrap></funding-source><award-id>NSF-1841811</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Legoretta Cancer Center Endowment Fund</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Breast Cancer Research Foundation of Alabama</institution><institution-id institution-id-type="DOI">10.13039/100016419</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Mitchell Cancer Institute Molecular &amp; Metabolic Oncology Program Development Fund</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Legoretta Cancer Center Endowment Fund</institution></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="23"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="SEC1"><title>Introduction</title><p>Protein mono-ADP-ribosylation (MARylation) and poly-ADP-ribosylation (PARylation) are post-translational modifications catalyzed by the ADP-ribose polymerase family of enzymes [<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B4" ref-type="bibr">4</xref>]. MARylation is the transfer of one ADP-ribose unit, whereas PARylation involves the successive transfer of multiple ADP-ribose units, poly(ADP-ribose) (PAR), to specific residues within target proteins [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B5" ref-type="bibr">5</xref>]. There are 17 proteins in the PARP family of enzymes [<xref rid="B1" ref-type="bibr">1</xref>], yet only PARP1, PARP2, PARP5a, and PARP5b catalyze the formation of PAR chains [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Of these, only PARP1 and PARP2 synthesize PAR in response to DNA breaks [<xref rid="B1" ref-type="bibr">1</xref>], which in turn facilitates the regulation of the DNA damage response (DDR) and impacts chromatin reorganization, transcription, mitosis, and cell death [<xref rid="B8" ref-type="bibr">8</xref>&#8211;<xref rid="B10" ref-type="bibr">10</xref>].</p><p>PAR plays a critical role in DNA repair by acting as a signaling platform to promote the recruitment of DNA repair factors as mediated via their PAR-binding domains (PBDs) [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B11" ref-type="bibr">11</xref>&#8211;<xref rid="B15" ref-type="bibr">15</xref>] to sites of DNA damage to promote, primarily, base excision repair (BER) and single-strand break repair (SSBR) [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. Other DNA repair pathway proteins shown to be regulated by PARP1/PARP2 activation include MutS&#945; and mismatch repair (MMR) [<xref rid="B16" ref-type="bibr">16</xref>], UV damage repair via DDB2/XPC and nucleotide excision repair (NER) [<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>], and DNA polymerase theta (Pol &#952;)-mediated end-joining (TMEJ) [<xref rid="B19" ref-type="bibr">19</xref>].</p><p>The involvement of PARP1 and PARP2 in BER and SSBR has been well documented [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B20" ref-type="bibr">20</xref>&#8211;<xref rid="B22" ref-type="bibr">22</xref>]. As we and many others have shown, the formation of a DNA single-strand break, whether mediated by a bifunctional DNA glycosylase to initiate BER, by the endonuclease APE1 during BER, or directly from DNA damage to initiate SSBR, gives rise to PARP1/PARP2 activation [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B20" ref-type="bibr">20</xref>]. The model for the canonical BER mechanism suggests that APE1 binds to and hydrolyzes apurinic or apyrimidinic (AP) sites in DNA [<xref rid="B23" ref-type="bibr">23</xref>], forming the DNA break that activates PARP1/PARP2, highlighting a functional relationship between APE1 and PARP1 [<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>]. In short, canonical BER and SSBR respond to base damage or single-strand DNA breaks (SSBs) in all phases of the cell cycle, followed by PARP1/PARP2 activation [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>]. Once activated, PARylation facilitates recruitment of the scaffold protein XRCC1 and the end- and gap-processing BER/SSBR proteins POLB, APTX, APLF, PNKP, and LIG3 [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. The recruitment of these BER/SSBR proteins to sites of DNA damage is PARP1- and PARP2-dependent, and some (POLB, APTX, LIG3) are also XRCC1-dependent [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>]. There is a reciprocal relationship between PARP1, PARP2, XRCC1, and POLB since loss of either XRCC1 or POLB delays release of PARP1 from sites of DNA damage, whereas PARP2 release is only dependent on XRCC1 [<xref rid="B13" ref-type="bibr">13</xref>]. Conversely, the release of the BER proteins XRCC1, POLB, APTX, and LIG3 from DNA damage sites is regulated by both PAR and NAD<sup>+</sup> levels [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. Once repair is complete, the removal of the damage signal (PAR) is mediated by the PAR-degrading enzymes PARG, TARG1, and ARH3 [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B20" ref-type="bibr">20</xref>]. Of note, the inhibition of PARG, but not TARG1, attenuates the release of these BER factors from sites of DNA damage, blocking the completion of BER and promoting persistent PAR levels and PAR signaling [<xref rid="B30" ref-type="bibr">30</xref>&#8211;<xref rid="B32" ref-type="bibr">32</xref>].</p><p>Replication stress and the activation of the DDR are hallmarks of the cancer phenotype [<xref rid="B33" ref-type="bibr">33</xref>&#8211;<xref rid="B35" ref-type="bibr">35</xref>], highlighting numerous potential cancer-specific targets that may be exploited for selective therapy approaches. Replication stress results from DNA lesions and unusual DNA structures (hairpins, triplexes, G-quadruplexes) encountered by the replication fork [<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>], as well as from oncogene activation or tumor suppressor gene inactivation [<xref rid="B38" ref-type="bibr">38</xref>]. Further, replication stress may result from defects in the nucleotide pool or altered expression of replication machinery proteins [<xref rid="B39" ref-type="bibr">39</xref>], from head-on collisions with the transcription machinery and the resulting accumulation of R-loops [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>], as well as DNA single-stranded gaps due to defects in Okazaki fragment processing [<xref rid="B42" ref-type="bibr">42</xref>] or BRCA1/2 expression and function [<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>]. In this regard, activation of PARP1/PARP2 and the resulting synthesis of PAR play a critical role in the DDR in response to stalled replication forks [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B45" ref-type="bibr">45</xref>&#8211;<xref rid="B57" ref-type="bibr">57</xref>], R-loops [<xref rid="B58" ref-type="bibr">58</xref>], single-stranded DNA gaps [<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B60" ref-type="bibr">60</xref>], DNA damage at telomeres [<xref rid="B61" ref-type="bibr">61</xref>&#8211;<xref rid="B63" ref-type="bibr">63</xref>], and G-quadruplexes [<xref rid="B63" ref-type="bibr">63</xref>&#8211;<xref rid="B65" ref-type="bibr">65</xref>], among other genome disturbances, such as DNA strand breaks formed during ribonucleotide excision repair (RER) [<xref rid="B66" ref-type="bibr">66</xref>] or by unligated Okazaki fragments [<xref rid="B67" ref-type="bibr">67</xref>].</p><p>The role of PARP1/PARP2 in protecting cells from DNA damage at the replication fork is exploited in homologous recombination (HR)-deficient (BRCA1 or BRCA2) tumors, as loss of BRCA1 or BRCA2, due to mutational inactivation, causes a synthetic lethal interaction with PARP inhibitors (PARPi) [<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>]. Conversely, PARG interacts with PCNA at the replication fork to counteract prolonged replication stress [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>]. PARG inhibitors (PARGi) cause accumulation of PAR at the replication fork [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B67" ref-type="bibr">67</xref>], slow down fork progression, cause the accumulation of single-stranded DNA gaps, suppress fork restart by perturbing RECQ1 helicase activity, and induce the activation of the ATR/CHK1 S-phase checkpoint [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B72" ref-type="bibr">72</xref>&#8211;<xref rid="B75" ref-type="bibr">75</xref>]. Despite demonstrated efficacy in some cell lines, PARG inhibition was shown to be minimally responsive in numerous patient-derived ovarian cancer cells and cell lines [<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B76" ref-type="bibr">76</xref>], as well as in glioma cell lines, glioma stem cells (GSCs), and head and neck cancer cells, among others [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B77" ref-type="bibr">77</xref>]. More recently, we have shown that defects in XRCC1, FEN1, or POLB expression or activity lead to elevated levels of PAR in replicating GSCs, glioma cells, ovarian cancer cells, and head &amp; neck cancer cells, leading to activation of the PAR-induced S-phase checkpoint [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>].</p><p>These earlier studies formed the basis for this study, where we demonstrate that XRCC1, POLB, APTX, and LIG3, but not APE1, regulate the activation of PARP1/PARP2 during replication, in what may be called replication-associated BER/SSBR. These BER and SSBR factors each regulate the cellular response to PARP inhibitors, further documenting a role for these proteins in suppressing the activation and cellular dependence on PARP1/PARP2. In addition, we show that these BER/SSBR proteins regulate the level of replication-dependent PAR levels and, in turn, suppress the cellular response to PARG inhibition, likely blocking the accumulation of replication-induced single-strand DNA gaps that have been suggested to modulate PARG inhibitor efficacy [<xref rid="B46" ref-type="bibr">46</xref>]. We show that modulation of replication-stress-mediated PAR levels, in response to PARG inhibition, leads to hyperactivation of the S-phase checkpoint that implicates the ATR/CHK1 signaling node [<xref rid="B8" ref-type="bibr">8</xref>] and ultimately replication catastrophe as revealed by elevated KAP1 phosphorylation. Further, we find that Protein Arginine Methyltransferase (PRMT) [<xref rid="B79" ref-type="bibr">79</xref>] isoforms 1 and 5, reported to catalyze asymmetric (PRMT1) and symmetric (PRMT5) dimethyl substitutions at arginine residues, and targets ATR [<xref rid="B80" ref-type="bibr">80</xref>&#8211;<xref rid="B82" ref-type="bibr">82</xref>], synergize with PARG inhibitors. Overall, we suggest that these studies implicate replication-associated BER/SSBR and PARylation in the activation of the PRMT1/PRMT5/ATR axis and highlight the crucial role of replication-associated BER/SSBR in protecting the cell during S-phase to suppress PARylation-induced checkpoint activation and replication catastrophe.</p></sec><sec sec-type="materials|methods" id="SEC2"><title>Materials and methods</title><p>All reagents, including antibodies, inhibitors, cell lines, oligonucleotides/gRNAs, recombinant DNA, software, and algorithms, used in this study are listed in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>, including catalog # and source.</p><sec id="SEC2-1"><title>Chemicals and reagents</title><p>The NAD<sup>+</sup> precursor NRH (dihydronicotinamide riboside; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-4H-pyridine-3-carboxamide) was prepared as described [<xref rid="B83" ref-type="bibr">83</xref>]. Briefly, powdered NRH was dissolved in molecular-grade sterile water to prepare a stock solution of 100 mM. Thymidine was freshly prepared as a 10 mM solution in PBS just before use. PARG inhibitor (PDD00017273), ATR inhibitor (Ceralasertib, AZD6738), ATM inhibitor (KU-55933), CHK1 inhibitor (MK8776), DNA-PK inhibitor (KU-57788), PRMT1 inhibitor (GSK3368715), PRMT5 inhibitor (PRT543), and PARP1/PARP2 inhibitors BMN-673, ABT-888, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AG014699">AG014699</ext-link>, MK-4827, and AZD2281, were kept as 10 mM DMSO stocks. All stock solutions were stored at &#8722;80&#176;C.</p></sec><sec id="SEC2-2"><title>Cell lines</title><p>The LN428 cell line is a human glioblastoma-derived cell line with mutations in the <italic toggle="yes">TP53</italic> gene and deletions in the p14ARF and p16 genes, as previously described [<xref rid="B84" ref-type="bibr">84</xref>]. PE01 and C4-2 cell lines were generous gifts from Dr Sharon Cantor (University of Massachusetts, USA) and Dr Toshiyasu Taniguchi (Tokai University School of Medicine, Japan), respectively [<xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B86" ref-type="bibr">86</xref>]. The BRCA2-deficient PE01 cell line was derived from an ovarian cancer patient. The BRCA2-proficient &#8220;revertant&#8221; C4-2 cell line was derived from PE01 and acquired resistance to both cisplatin and PARPi due to a secondary mutation restoring BRCA2 function [<xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B86" ref-type="bibr">86</xref>]. ES-2 is an ovarian clear-cell carcinoma cell line. 293-FT cells were derived from human embryonic kidney cells transformed with the SV40 large T antigen. RPE-1 cells are hTERT-immortalized retinal pigment epithelial cells [<xref rid="B87" ref-type="bibr">87</xref>]. Cell lines were routinely validated by Genetica Cell Line Testing. Mycoplasma contamination was monitored bimonthly using Lonza MycoAlert<sup>&#174;</sup>. Cells at passage number 15 or lower were used for all experiments.</p><p>LN428, LN428/PARP2-KO, LN428/PARP1-KO/PARP2-KO, LN428/POLB-KO, LN428/APTX-KO, LN428/LIG3-KO, LN428/LivePAR, and LN428/XRCC1-KO/LivePAR cells were cultured in MEM Alpha supplemented with 10% heat-inactivated (HI) fetal bovine serum (FBS), <sc>l</sc>-glutamine, and Antibiotic-Antimycotic. LN428/PARP1-KO and LN428/XRCC1-KO cells were additionally supplemented with puromycin (1 &#181;g/ml). LN428/PARP1&#8211;XRCC1/Split-TurboID cells were supplemented with both hygromycin (200 &#181;g/ml) and puromycin (1 &#181;g/ml). During experiments, hygromycin and/or puromycin were omitted. ES-2, ES-2/XRCC1-KO, ES-2/POLB-KO, ES-2/APTX-KO, ES-2/LIG3-KO, PEO1, C4-2, C4-2/XRCC1-KO, C4-2/POLB-KO, C4-2/APTX-KO, and C4-2/LIG3-KO cells were cultured in RPMI supplemented with 10% HI FBS, <sc>l</sc>-glutamine, and penicillin-streptomycin. ES-2/PARP1&#8211;XRCC1/Split-TurboID cells were additionally supplemented with puromycin (1 &#181;g/ml). RPE-1, RPE-1/APE1-KO, and RPE-1/XRCC1-KO cells were cultivated in DMEM/F12 supplemented with GlutaMAX and 10% HI FBS. All cells were cultured in a humidified incubator at 37&#176;C with 5% CO<sub>2</sub>.</p></sec><sec id="SEC2-3"><title>Transfection, lentivirus production, and cell transduction</title><sec id="SEC2-3-1"><title>Transfection</title><p>ES-2/PARP1&#8211;XRCC1/Split-TurboID cells were created by transfecting the pLV-Puro-EF1A-HA-PARP1-3xGS-TurboC-T2A-XRCC1-myc-3xGS-TurboN construct into ES-2 cells using polyethylenimine hydrochloride (PEI) (#24765; Polysciences), and stable clones were selected using puromycin. Plasmid DNA (1 &#181;g) was mixed with 4 &#181;g PEI in 1 ml serum and antibiotic-free media. Following 30 min incubation, the DNA/PEI complex was added to 80% confluent ES-2 cells in a 60 mm Petri dish, dropwise. Following 8 h of incubation, the medium was changed, and selection for stable clones started 48 h later in media supplemented with puromycin (1 &#181;g/ml).</p></sec><sec id="SEC2-3-2"><title>Virus production</title><p>293-FT cells were used to generate lentivirus expressing Cas9/sgRNA, LivePAR, or the Split-TurboID expression vectors. Cells (1&#160;&#215;&#160;10<sup>6</sup> cells/dish) were seeded onto a 60 mm petri dish and allowed to grow overnight. Packaging vectors pMDLg/pRRE, pRSV-Rev, and pMD2.G, and the shuttle/transfer vector were co-transfected into 293-FT cells using the TransIT-X2 Dynamic Delivery System. The supernatant containing the lentivirus was collected 48 h later and filtered using 0.45 &#956;m filters to remove cell debris and isolate the viral particles, as described previously [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B31" ref-type="bibr">31</xref>].</p></sec><sec id="SEC2-3-3"><title>Transduction</title><p>Target cells (2&#160;&#215;&#160;10<sup>5</sup> cells/well) were seeded onto a six-well plate and incubated for 24 h. The media was replaced with 1 ml of media containing polybrene (2 &#956;g/ml), followed by dropwise addition of the lentiviral particle solution (1 ml). After overnight incubation at 32&#176;C, the lentivirus-containing media was replaced with fresh media, and the cells were allowed to grow for 48 h before adding selection media.</p></sec></sec><sec id="SEC2-4"><title>Lentiviral-mediated knockout of <italic toggle="yes">PARP1</italic> and <italic toggle="yes">XRCC1</italic> by CRISPR/Cas9 in LN428 cells</title><p>A lentiviral vector derived from pLentiCRISPRv2, expressing Cas9 and either a PARP1 guide RNA (gRNA) targeting exon 1 or an XRCC1 gRNA targeting exon 3, was generously provided by Dr Wim Vermeulen (Erasmus MC, Netherlands) [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B88" ref-type="bibr">88</xref>]. Lentiviruses were prepared, and LN428 cells were transduced as previously described [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. Following overnight transduction with either the PARP1-KO or XRCC1-KO gRNA virus, the media were replaced with fresh media, and cells were allowed to propagate to confluence. Cells were then subjected to puromycin selection (1 &#181;g/ml) for 2 weeks. Knockout validation was performed by immunoblotting, using a PARP1 antibody for PARP1-KO cells and an XRCC1 antibody for XRCC1-KO cells. H3 protein expression served as the loading control.</p></sec><sec id="SEC2-5"><title>Non-viral-mediated knockout of <italic toggle="yes">PARP2, XRCC1, POLB, APTX</italic>, or <italic toggle="yes">LIG3</italic> in LN428, ES-2, or C4-2 cells</title><p>
<italic toggle="yes">PARP2</italic> was knocked out in LN428 and LN428/PARP1-KO cells; <italic toggle="yes">XRCC1</italic> in ES-2 and C4-2 cells; <italic toggle="yes">POLB</italic> in LN428, ES-2, and C4-2 cells; <italic toggle="yes">APTX</italic> in LN428, ES-2, and C4-2 cells; and <italic toggle="yes">LIG3</italic> in LN428, ES-2, and C4-2 cells. Cells were seeded at a density of 2&#160;&#215;&#160;10<sup>5</sup> cells/well in a six-well plate and incubated for 24 h. The non-viral ribonucleoprotein (RNP) transfection complex, purchased from Synthego Corporation, was prepared by combining three single guide RNAs (sgRNAs) targeting an early exon of each respective gene&#8212;<italic toggle="yes">PARP2, XRCC1, POLB, APTX</italic>, or <italic toggle="yes">LIG3&#8212;</italic>with purified Cas9 protein and the CRISPRMAX-Cas9 transfection reagent in serum-free OptiMEM. Transfection complexes were incubated for 30 min before dropwise addition to the cells. Two to three days later, the medium containing the transfection reagent was replaced with fresh medium, and the cells were allowed to propagate to confluence. Knockout validation was confirmed by immunoblot analysis of whole-cell lysates, compared to a non-targeted control. The following antibodies were used: anti-PARP2, anti-XRCC1, anti-POLB, anti-APTX, and anti-LIG3. H3 was used as a loading control.</p></sec><sec id="SEC2-6"><title>Cell protein lysate preparation</title><p>Protein extracts were prepared from parental and genetically modified human cancer cells using 2&#215; clear Laemmli buffer (2% SDS, 20% glycerol, 62.5 mM Tris&#8211;HCl, pH 6.8) as previously described [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B89" ref-type="bibr">89</xref>]. Generally, an equal number of cells (2&#8211;3 &#215; 10<sup>5</sup>) were seeded in six-well plates and allowed to reach 60%&#8211;80% confluency after 24 h of culture. Following treatment with varying times and concentrations (as indicated in the figures), the treatment medium was removed, and the cells were washed twice with PBS. Subsequently, 100&#8211;200 &#181;l of 2&#215; clear Laemmli buffer was added, the cells were scraped using a cell scraper, and the lysate was transferred to a 1.5 ml Eppendorf tube, followed by heating to 95&#176;C for 5 min. Protein concentrations were determined using a NanoDrop 2000c Spectrophotometer [<xref rid="B90" ref-type="bibr">90</xref>].</p></sec><sec id="SEC2-7"><title>Immunoblot</title><p>Equal amounts of whole-cell lysate (30&#8211;50 &#181;g protein) were loaded into each well of Novex 4%&#8211;12% Bis-Tris gels and subjected to electrophoresis at 100&#8211;120 V for 1.5 h. Proteins were separated by sodium dodecyl sulfate&#8211;polyacrylamide gel electrophoresis (SDS&#8211;PAGE) and transferred to mini-nitrocellulose membranes (0.2 &#181;m) using the Trans-Blot Turbo transfer system (Bio-Rad) for 18 min. Membranes were blocked with 5% blotting-grade non-fat milk powder in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 h at room temperature. Following blocking, membranes were probed overnight with primary antibodies (as indicated in the figure legends), followed by three 10-min washes in TBST. Subsequently, membranes were probed with a secondary antibody (goat anti-mouse/rabbit-HRP conjugated). The protein bands were then detected using Clarity Western ECL Substrate. To determine the induction factors (I.F.) of pCHK1 (S345) and pCHK1 (S317) upon PARG and/or ATR, ATM, and DNA-PK inhibition (as shown in Fig. <xref rid="F6" ref-type="fig">6A</xref>), a densitometry analysis of the immunoblots was performed using ImageJ. First, the relative amounts of H3 were determined to account for differences in loading. Then, taking into account these differences, the relative amounts of pCHK1 (S345) and pCHK1 (S317) in the treated samples were expressed as a factor compared to the control.</p></sec><sec id="SEC2-8"><title>Cell cycle synchronization</title><sec id="SEC2-8-1"><title>Double thymidine block</title><p>To synchronize ES-2 cells at the G1/S-phase border, the double thymidine block approach was used [<xref rid="B91" ref-type="bibr">91</xref>]. Briefly, cells were seeded at a density of 1&#160;&#215;&#160;10<sup>6</sup> cells in a 100 mm dish and incubated for 24 h. Cells were then treated with 2 mM thymidine for 24 h, followed by release into fresh medium for 8 h. Subsequently, cells were re-treated with 2 mM thymidine for an additional 24 h. The arrested/synchronized cells (with no DNA replication) were then released into fresh medium for 0 (no replication), 2, 4, 6, or 8 h. Cell cycle analysis was performed on both the thymidine-arrested and released groups to confirm the degree of synchronization. Following confirmation of proper synchronization in the G1-phase of the cell cycle (non-replicating) or release into the S-phase of the cell cycle (replicating), a PAR assay was performed for each condition to determine the level of PAR in resting versus replicating cells.</p></sec><sec id="SEC2-8-2"><title>Serum starvation</title><p>To synchronize LN428 or the LN428/PARP1&#8211;XRCC1/Split-TurboID cells at the G1/S-phase border, serum starvation [<xref rid="B92" ref-type="bibr">92</xref>] was employed, followed by release into the S-phase of the cell cycle. Serum-free media was used to seed 1&#8211;1.5&#160;&#215;&#160;10<sup>6</sup> cells onto 100 mm or 150 mm dishes and incubated for 24 h. One group of cells (released from serum starvation, replicating) was then released into serum-enriched fresh media for the times indicated in the figure legends (replicating). Another group of cells (continuously serum-starved, non-replicating) was maintained in serum-free media for up to 24 h. Cell cycle analysis was performed on both groups using either Hoechst staining with the Nexcelom Celigo Imaging Cytometer (Perkin Elmer) or PI staining by flow cytometry. Following confirmation of proper synchronization into the G1-phase of the cell cycle (non-replicating) or S-phase of the cell cycle (replicating), the PAR assay and Split-TurboID experiments were performed.</p></sec><sec id="SEC2-8-3"><title>CDK4/6 inhibition</title><p>To synchronize ES-2/PARP1&#8211;XRCC1/Split-TurboID cells in G1, the CDK4/6 inhibitor (CDK4/6i) ribociclib was used [<xref rid="B93" ref-type="bibr">93</xref>]. Cells were exposed to 2 &#181;M CDK4/6i for 48 h. Cells were then released from the G1 arrest and allowed to enter S-phase by media change, or not, for 6 h. During these 6 h, cells were exposed to 10 &#181;M PARGi and 100 &#181;M NRH. One hour before the end of the 6 h, 100 &#181;M biotin was added to the cells.</p></sec></sec><sec id="SEC2-9"><title>PAR analysis by immunoblot</title><p>To analyze replication-dependent PAR synthesis, parental and BER/SSBR-modified cells were treated with vehicle (DMSO), the NAD<sup>+</sup> precursor NRH (100 &#956;M), the PARG inhibitor PDD00017273 (10 &#956;M), or the combination of NRH and PARGi (same doses) for the times indicated in the figures. Following treatment, cells were washed twice with PBS, trypsinized, and equal numbers of cells (3&#160;&#215;&#160;10<sup>6</sup>) from each treatment condition were processed for lysate preparation using 2&#215; clear Laemmli buffer (2% SDS, 20% glycerol, 62.5 mM Tris&#8211;HCl, pH 6.8), a buffer optimal for preparing cell lysates for PAR analysis. The immunoblot was then performed as described.</p></sec><sec id="SEC2-10"><title>Immunofluorescence</title><p>Colocalization of PAR and pRPA(S4/S8) foci was quantified by confocal microscopy, as previously described [<xref rid="B94" ref-type="bibr">94</xref>]. Shortly, LN428/LivePAR and LN428/XRCC1-KO/LivePAR cells were plated onto microscope coverslips in 60 mm Petri dishes. Before use, the coverslips were prepared by first washing them in diethyl ether, then in decreasing concentrations of ethanol, then in 1N HCl, and finally in ddH<sub>2</sub>O. Two days after plating, the cells were exposed to 10 &#181;M PARGi and 100 &#181;M NRH for 8 h. Following exposure, the cells were first prefixed in 4% formaldehyde in PBS (15 min, room temperature) and then in methanol:acetone (7:3, 9 min, &#8722;20&#176;C). The first antibody [anti-pRPA(S4/S8)] was added overnight (4&#176;C), and the second antibody was added for 2&#8211;3 h at room temperature. The coverslips were mounted onto glass slides in Vectashield (H-1000) containing DAPI. The fluorescence signals for EGFP (LivePAR), Alexa Fluor<sup>&#174;</sup> 568 [pRPA(S4/S8)], and DAPI (DNA) were detected, imaged, and quantified using a Nikon Ti2-E inverted confocal microscope at a 63&#215; (N. A. 1.42) magnification. The microscope is equipped with Ax-R and Ax-R 2k Resonant + Galvo Scan Head. Foci were scored in the ImageJ software.</p></sec><sec id="SEC2-11"><title>Caspase-3/7 activity assay</title><p>To measure Caspase-3/7 activity in response to PARGi treatment, LN428 and the corresponding BER/SSBR-KO cells were seeded in a 96-well plate (5000 cells/well) and incubated overnight. Both WT and BER/SSBR-KO cells were treated with PARGi (10 &#181;M) for 24, 48, and 72 h. For Caspase-3/7 activation analysis, a mixture of ViaStain Live Caspase-3/7 substrate (2 &#181;M) and Hoechst 33342 (2 &#181;M) was added to both control and treated wells without removing preconditioned media. The plates were then incubated at 37&#176;C for 1 h. Caspase-3/7 activity was determined using a Celigo S Image Cytometer (Nexcelom Bioscience, Perkin Elmer) by capturing the Caspase-3/7 signal (green, excitation/emission wavelength: 490 nm/520 nm) merged with the nuclear signal (blue, excitation/emission wavelength: 377 nm/470 nm). The total number of cells exhibiting Caspase-3/7 positivity was quantified on 2D scatter plots (green intensity versus blue intensity) using the built-in gating interface of the Celigo S Image Cytometer, as described [<xref rid="B95" ref-type="bibr">95</xref>].</p></sec><sec id="SEC2-12"><title>Cell cycle analysis</title><p>Cell synchronization in the G1 phase of the cell cycle and release into the S phase of the cell cycle were determined by flow cytometric analysis. Both serum-starved/thymidine-arrested and released cells were trypsinized, centrifuged, and washed twice with ice-cold PBS. An equal number of cells (1 &#215; 10<sup>6</sup>) from each condition were fixed overnight with 70% ethanol at &#8722;30&#176;C. The cells were then washed twice with PBS and resuspended in 0.5 ml FxCycle&#8482; PI/RNase staining solution and incubated for 30 min at room temperature. Flow cytometry was used to determine DNA content (FACS Canto II, BD Biosciences, San Jose, CA). Modfit LT Software V4.1 was used to generate a cell cycle distribution model. Alternatively, cell cycle analysis was performed using Hoechst staining with the Nexcelom Celigo Imaging Cytometer (Perkin Elmer).</p></sec><sec id="SEC2-13"><title>Cell viability assay</title><p>Cell viability in response to drug treatment (PARPi, PARGi, ATRi, ATRi&#160;+&#160;PARGi, CHKi, CHKi&#160;+&#160;PARGi, PRMT1i, PRMT5i, PRMT1i&#160;+&#160;PARGi, and PRMT5i&#160;+&#160;PARGi) was determined as described [<xref rid="B75" ref-type="bibr">75</xref>]. Shortly, cells were seeded onto a 96-well plate (800 cells/well). After 24 h of incubation, cells were treated with a single or combined dose (multiple dilutions as indicated in the figures) without removing preconditioned media. After 120 h (5 days), total and dead cells were stained with Hoechst 33342 (2 &#181;M) and Propidium Iodide (1.5 &#181;M), respectively, followed by 15 min of incubation at 37&#176;C. Total and dead cells were counted using a Celigo S Image Cytometer (Nexcelom Bioscience, Perkin Elmer) by capturing the Hoechst dye signal (excitation/emission wavelength for the blue channel: 377 nm/470 nm) and the PI signal (excitation/emission wavelength for the red channel: 531 nm/629&#160;nm).</p></sec><sec id="SEC2-14"><title>Split-TurboID experiments for determining PARP1/XRCC1 interacting partners</title><p>To label transient and stable interacting proteins in proximity of the PARP1/XRCC1 complex that forms in response to DNA damage, we employed a Split-TurboID approach [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B96" ref-type="bibr">96</xref>]. For this approach, the biotinylation protein TurboID was split into an N-terminal domain (N-TurboID) and a C-terminal domain (C-TurboID) [<xref rid="B96" ref-type="bibr">96</xref>]. The N-TurboID domain was fused in-frame to the C-terminus of XRCC1 to create the plasmid pLV-Puro-EF1A-XRCC1-Myc-4GS-TurboN, also encoding the gene for puromycin selection. The C-TurboID domain was fused in-frame to the C-terminus of PARP1 to create the plasmid pLV-Hygro-EF1A-3xHA-PARP1-4GS-TurboC, also encoding the gene for hygromycin selection. These plasmids were designed in-house and obtained from VectorBuilder. PARP1/Split-TurboID and XRCC1/Split-TurboID lentiviruses were prepared as described, and LN428 cells were transduced with each separately. Expression of both fusion proteins was confirmed by immunoblot, and cells were maintained with concurrent treatment with hygromycin and puromycin.</p><p>Using this Split-TurboID method, PARP1/XRCC1 interacting proteins were determined under replicating versus non-replicating conditions. LN428/PARP1&#8211;XRCC1/Split-TurboID cells were subjected to serum starvation as described above to create replicating and non-replicating cell groups before biotin labeling. Cells (5 &#215; 10<sup>6</sup>) were seeded onto a 150 mm dish, and after 24 h of incubation, the medium was supplemented with DMSO (control) or biotin (100 &#956;M) for 1 h (two plates for each group). Biotinylation was halted by placing the cell plates on ice, followed by a wash with ice-cold PBS. Cells were harvested with a cell scraper, then lysed with an equal volume of lysis buffer [1% SDS, 10 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0, 50 mM Tris&#8211;HCl, pH 8.0, protease inhibitors]. Protein lysates were quantified using the NanoDrop 2000c Spectrophotometer [<xref rid="B90" ref-type="bibr">90</xref>]. An equal quantity of proteins was incubated overnight with Streptavidin Mag Sepharose beads (100 &#956;l). Biotinylated proteins on the beads were washed three times each with Wash buffer-1 (0.2% SDS in water, protease inhibitors), Wash buffer-2 (0.1% deoxycholate, 1% Triton X-100, 500 mM NaCl, 1 mM EDTA, 50 mM HEPES pH 7.5, protease inhibitors), Wash buffer-3 (50 mM LiCl, 0.5% NP40, 0.5% deoxycholate, 1 mM EDTA, 10 mM Tris pH 8.1, protease inhibitors), Wash buffer-4 (50&#160;mM Tris pH 7.4, 50 mM NaCl, protease inhibitors), and eluted from the beads with elution buffer (2% SDS, 20% glycerol, 62.5 mM Tris&#8211;HCl, pH 6.8, 0.01% bromophenol blue, 2 mM biotin) and heating to 95&#176;C for 5 min. Eluted proteins were then probed by immunoblot for BER/SSBR proteins and replication marker proteins.</p></sec><sec id="SEC2-15"><title>Graphics</title><p>The Graphical Abstract was created in BioRender. Sobol, R. (2025) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com/s2&#xD7;0qaw" ext-link-type="uri">https://BioRender.com/s2&#215;0qaw</ext-link>. The graphics for Figs <xref rid="F2" ref-type="fig">2A</xref> and&#160;<xref rid="F2" ref-type="fig">B</xref> and&#160;<xref rid="F7" ref-type="fig">7G</xref> were also created in BioRender, as described in the figure legends.</p></sec><sec id="SEC2-16"><title>Data analysis</title><p>Data are shown as the mean &#177; standard deviation from 2&#8211;3 independent experiments. The Student&#8217;s <italic toggle="yes">t</italic>-test was used for comparisons between the two groups. Two-way ANOVA was used for multiple comparisons. The significance between the control and experimental groups is indicated by <italic toggle="yes">P</italic>-values. <italic toggle="yes">P</italic>-values are indicated by asterisks with <sup>&#8727;</sup><italic toggle="yes">P</italic> &lt; .05,&#160;<sup>&#8727;&#8727;</sup><italic toggle="yes">P</italic> &lt; .01,&#160;<sup>&#8727;&#8727;&#8727;</sup><italic toggle="yes">P</italic> &lt; .001, <sup>&#8727;&#8727;&#8727;&#8727;</sup><italic toggle="yes">P</italic> &lt; .0001. GraphPad PRISM v10.5.0 was used for statistical analysis. Synergy calculations were made using the Bliss independence model [<xref rid="B97" ref-type="bibr">97</xref>], essentially as we have described previously [<xref rid="B75" ref-type="bibr">75</xref>]. Briefly, an Excess Over Bliss value above 0 indicates synergy, while a score of 0 indicates independent additivity and a score less than zero indicates antagonism between the two drugs, as described in [<xref rid="B97" ref-type="bibr">97</xref>].</p></sec></sec><sec sec-type="results" id="SEC3"><title>Results</title><sec id="SEC3-17"><title>PAR is synthesized in a PARP1, PARP2, and replication-dependent manner</title><p>Both PARP1 and PARP2 contribute to DNA damage-induced PAR synthesis [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B98" ref-type="bibr">98</xref>]. In GSCs, we have recently shown that both DNA damage-induced and replication-dependent PARylation are enhanced when supplemented with the NAD<sup>+</sup> precursor NRH [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. PARG inhibitor (PARGi)-induced accumulation of PAR in GSCs is primarily dependent on PARP1 [<xref rid="B31" ref-type="bibr">31</xref>], while in several other cancer cells, PARP2 was found to have a minor but important role in DNA damage-induced and replication-dependent PARylation [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. We have expanded on these studies here to define the involvement of both PARP1 and PARP2 in replication-dependent PARylation. We selected ES-2 cells, an ovarian cancer cell line reported to have a high level of replication stress [<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B100" ref-type="bibr">100</xref>], and the glioma cell line LN428 that contains a mutation in <italic toggle="yes">TP53</italic> and a deletion of the p16(INK4a) (<italic toggle="yes">CDKN2A</italic>) gene [<xref rid="B101" ref-type="bibr">101</xref>&#8211;<xref rid="B104" ref-type="bibr">104</xref>], also giving rise to elevated levels of replication stress [<xref rid="B105" ref-type="bibr">105</xref>, <xref rid="B106" ref-type="bibr">106</xref>].</p><p>To reveal the level of replication-dependent PAR accumulation [<xref rid="B107" ref-type="bibr">107</xref>], PAR levels were evaluated by immunoblot in asynchronously cycling LN428 and ES-2 cells that were exposed for 8 h to NRH (100 &#181;M), the model PARG inhibitor PDD00017273 (10 &#181;M), or NRH + PARGi, with DMSO-exposed cells used as controls. Consistent with our earlier studies [<xref rid="B31" ref-type="bibr">31</xref>], PARGi treatment stabilized PAR levels that were further elevated in the presence of the NAD<sup>+</sup>-precursor NRH in both LN428 cells (Fig.&#160;<xref rid="F1" ref-type="fig">1A</xref>) and ES-2 cells (Fig.&#160;<xref rid="F1" ref-type="fig">1B</xref>). To define the role of both PARP1 and PARP2 in response to replication stress, we used CRISPR/Cas9 to create PARP1-KO, PARP2-KO, and double PARP1/PARP2-KO in LN428 cells (Fig.&#160;<xref rid="F1" ref-type="fig">1C</xref>). Consistent with our earlier studies on laser-induced DNA damage [<xref rid="B13" ref-type="bibr">13</xref>], PAR levels were significantly reduced in the PARP1-KO cells as compared to the levels of PAR in the parental LN428 cells (Fig.&#160;<xref rid="F1" ref-type="fig">1D</xref>). Interestingly, the PAR chain length appears longer in the PARP2-KO cells, which is in line with earlier studies suggesting a role for PARP2 in PAR branching [<xref rid="B108" ref-type="bibr">108</xref>], while no PAR was observed in the double knockout LN428/PARP1-KO/PARP2-KO cells (Fig. <xref rid="F1" ref-type="fig">1D</xref>). As expected from our previous reports [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>], combining the PARGi PDD00017273 with the NAD<sup>+</sup> precursor molecule NRH led to an increase in PAR formation, as compared to PARGi alone (Fig. <xref rid="F1" ref-type="fig">1A</xref>, <xref rid="F1" ref-type="fig">B</xref>, and D). Overall, these studies confirm that both PARP1 and PARP2 are required for PAR synthesis in asynchronously cycling LN428 and ES-2 cells.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Replication-dependent PARP1/PARP2 activation. (<bold>A</bold>) PAR immunoblot of whole cell lysates prepared from LN428 cells exposed to vehicle (DMSO), NRH (100 &#956;M), PARGi (PDD00017273, 10 &#181;M), or NRH + PARGi for 8 h, with &#946;-ACTIN shown as a loading control. (<bold>B</bold>) PAR immunoblot of whole cell lysates prepared from ES-2 cells exposed to vehicle (DMSO), NRH (100 &#956;M), PARGi (PDD00017273, 10 &#181;M), or NRH + PARGi for 8 h, with &#946;-ACTIN shown as a loading control. (<bold>C</bold>) Immunoblot of PARP1, PARP2, and H3 (loading control) documenting PARP1-KO, PARP2-KO, and PARP1&#160;+&#160;PARP2 double-KO via CRISPR/Cas9 in LN428 cells. (<bold>D</bold>) PAR immunoblot of whole cell lysates prepared from LN428, LN428/PARP1-KO, LN428/PARP2-KO, and LN428/PARP1-KO/PARP2-KO cells exposed to PARGi (PDD00017273) or NRH + PARGi for 8 h, with &#946;-ACTIN shown as a loading control. (<bold>E</bold>) PAR immunoblot of whole-cell lysates prepared from LN428 cells (non-synchronized; Lanes 1&#8211;3), following serum starvation (synchronized/non-replicating cells; G1 phase, Lane 4), and after release following normal media replenishment (replicating; S-phase, Lanes 5&#8211;8). (<bold>F</bold>) PAR immunoblot of whole cell lysates prepared from ES-2 cells following double thymidine block (synchronized/non-replicating cells; G1 phase, Lane 1) and after release following normal media replenishment (replicating; S-phase, Lanes 2&#8211;5), with &#946;-ACTIN shown as a loading control.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="zcaf057fig1.jpg"/></fig><p>To evaluate whether PARP1/PARP2-mediated PARylation is dependent on replication, LN428 cells were synchronized in G1 by serum starvation. Cell synchronization in G1 and release into the S phase was confirmed using flow cytometric-based cell cycle analysis (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1A</xref>), which showed that releasing serum-starved cells caused them to slowly enter S phase in a time-dependent manner. Comparing PAR formation in replicating and non-replicating LN428 cells showed that PAR is synthesized in a replication-dependent manner (Fig.&#160;<xref rid="F1" ref-type="fig">1E</xref> and Supplementary Fig. <xref rid="sup1" ref-type="supplementary-material">S1B</xref>). Replication-dependent PAR formation was also confirmed in ES-2 cells by synchronizing cells with a double thymidine block (Fig. <xref rid="F1" ref-type="fig">1F</xref> and Supplementary Fig.&#160;<xref rid="sup1" ref-type="supplementary-material">S1D</xref>). PAR immunoblot of both the LN428 cells and the ES-2 cells shows excessive PAR formation within a short time after release into S phase, as compared to non-replicating cells (Fig.&#160;<xref rid="F1" ref-type="fig">1E</xref> and&#160;<xref rid="F1" ref-type="fig">F</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig.&#160;S1B</xref>).</p></sec><sec id="SEC3-18"><title>PARP1-mediated, replication-dependent PARylation recruits BER/SSBR factors XRCC1, POLB, APTX, and LIG3</title><p>DNA damage-induced PARP1 activation and the synthesis of PAR facilitate the recruitment of PAR-binding proteins such as XRCC1 that, in turn, recruit additional DNA repair factors via heterodimerization with XRCC1 [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>]. To identify proteins recruited to sites of replication-dependent PARP1 activation, we developed both a two-vector and a single-vector PARP1/XRCC1 Split-TurboID proximity labeling system [<xref rid="B109" ref-type="bibr">109</xref>], whereby proteins are biotinylated when the PARP1&#8211;XRCC1 complex is formed following PARP1 activation (Fig. <xref rid="F2" ref-type="fig">2A</xref>) and the TurboID protein is re-formed, allowing biotinylation of proximal proteins. Both an LN428 and an ES-2 cell line were created that each expresses Split-TurboID fusions for both PARP1-TurboC and XRCC1-TurboN. In this system, TurboID reconstitution (Turbo-N/Turbo-C) and biotinylation depend on the interaction of PARP1 with XRCC1, and in turn, biotinylated proteins can then be captured using magnetic streptavidin beads (Fig. <xref rid="F2" ref-type="fig">2B</xref>).</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Identification of BER/SSBR factors during replication. (<bold>A</bold>) Graphic depicting the PARP1&#8211;XRCC1 Split-TurboID system. The biotinylation protein TurboID was split into an N-terminal domain (Turbo-N) and a C-terminal domain (Turbo-C). The Turbo-N domain was fused in-frame to the C-terminus of XRCC1, while the Turbo-C domain was fused in-frame to the C-terminus of PARP1. Upon the induction of DNA damage or replication stress, the co-localization of XRCC1 and PARP1 causes the reassembly and activation of TurboID and the initiation of proximity biotinylation [<xref rid="B96" ref-type="bibr">96</xref>, <xref rid="B109" ref-type="bibr">109</xref>]. Created in BioRender. Sobol, R. (2025) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com/p82xg0b" ext-link-type="uri">https://BioRender.com/p82xg0b</ext-link>. (<bold>B</bold>) Graphic depicting the experimental outline of proximity labeling (PARP1&#8211;XRCC1/Split-TurboID) to capture activated PARP1&#8211;XRCC1 complexed proteins during replication. Created in BioRender. Sobol, R. (2025) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com/zoadg6m" ext-link-type="uri">https://BioRender.com/zoadg6m</ext-link>. (<bold>C</bold>) Streptavidin capture of biotinylated proteins in LN428/PARP1&#8211;XRCC1/Split-TurboID cells. Cells were arrested by serum starvation and then released from the block by media change. Arrested (&#8722;) and actively replicating (+) cells were exposed to biotin (100 &#181;M, 60 min) for 1 h. Biotinylated proteins were captured with streptavidin-coated beads and probed by immunoblot. (<bold>D</bold>) Streptavidin capture of biotinylated proteins in ES-2/PARP1&#8211;XRCC1/Split-TurboID cells. Cells were arrested in G1 for 48 h by CDK4/6 inhibition and then released from the block by media change. All cells were exposed to 10 &#181;M PARGi and 100 &#181;M NRH for 6 h, and biotinylation was then performed with 100 &#181;M biotin for 1 h. Biotinylated proteins were captured with streptavidin-coated beads and probed by immunoblot.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="zcaf057fig2.jpg"/></fig><p>To biotinylate BER/SSBR proteins that are recruited by the PARP1/XRCC1 complex in response to replication, the LN428/PARP1&#8211;XRCC1/Split-TurboID cells were synchronized using serum starvation (Fig. <xref rid="F2" ref-type="fig">2A</xref> and&#160;<xref rid="F2" ref-type="fig">B</xref>). Cell synchronization was confirmed by cell cycle analysis (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1C</xref>). Replicating and non-replicating cells were then supplemented with biotin (100 &#181;M) for 1 h, followed by streptavidin pull-down and immunoblotting to probe for key BER/SSBR factors (Fig. <xref rid="F2" ref-type="fig">2B</xref> and&#160;<xref rid="F2" ref-type="fig">C</xref>). In line with PAR levels &#177; replication (Fig. <xref rid="F1" ref-type="fig">1E</xref> and&#160;<xref rid="F1" ref-type="fig">F</xref> and Supplementary Fig.&#160;<xref rid="sup1" ref-type="supplementary-material">S1B</xref>), we observed an increase in biotinylation of both PARP1 and XRCC1 in replicating cells as compared to arrested cells (Fig.&#160;<xref rid="F2" ref-type="fig">2C</xref>). It is noted that there is a low level of PARP1 and XRCC1 biotinylation in resting cells (Fig. <xref rid="F2" ref-type="fig">2C</xref> and&#160;<xref rid="F2" ref-type="fig">D</xref>), suggesting there is evidence for minimal PARP1/XRCC1 complex formation in G1. However, consistent with the elevated levels of PAR upon replication, we find there is elevated replication-dependent activation/formation of the PARP1/XRCC1 complex in S-phase that then facilitates the interaction with the BER/SSBR proteins POLB, APTX, and LIG3 in LN428 cells (Fig.&#160;<xref rid="F2" ref-type="fig">2C</xref>) and recruitment of LIG3 in ES-2 cells (Fig.&#160;<xref rid="F2" ref-type="fig">2D</xref>). This is consistent with our earlier studies on the capture and identification of PAR-complexed proteins in response to alkylation damage [<xref rid="B10" ref-type="bibr">10</xref>]. However, unique to this study, we also find the replication marker RPA2 (Fig.&#160;<xref rid="F2" ref-type="fig">2C</xref>). However, consistent with a role for the BER factor APE1 acting upstream of PARP1 [<xref rid="B20" ref-type="bibr">20</xref>], we did not observe recruitment of APE1 upon PARP1 activation and formation of the PARP1/XRCC1 complex (Fig.&#160;<xref rid="F2" ref-type="fig">2D</xref>). Similarly, using PARP1-BioID analysis in arrested and replicating cells, we found enhanced biotinylation of XRCC1, PCNA, and ORC2 in replicating cells due to proximity to PARP1 [<xref rid="B31" ref-type="bibr">31</xref>]. In all, we suggest this confirms that BER and SSBR proteins are recruited to activated PARP1 during replication, likely in response to replication stress-induced PARP1 activation, which we term replication-associated BER/SSBR.</p></sec><sec id="SEC3-19"><title>XRCC1, POLB, APTX, and LIG3 suppress replication-dependent PARylation</title><p>In GSCs, loss of the BER/SSBR factor XRCC1 or inhibition of the BER enzyme FEN-1 significantly enhanced the level of replication-dependent PAR [<xref rid="B31" ref-type="bibr">31</xref>], consistent with the accumulation of BER intermediates [<xref rid="B110" ref-type="bibr">110</xref>, <xref rid="B111" ref-type="bibr">111</xref>], unprocessed Okazaki fragments [<xref rid="B67" ref-type="bibr">67</xref>], and/or the accumulation of single-stranded DNA gaps [<xref rid="B46" ref-type="bibr">46</xref>], each shown to enhance PARP1 activation. Further, loss of XRCC1 or POLB enhances binding of PARP1 and PARP2 to sites of DNA damage, promoting continued PARylation [<xref rid="B13" ref-type="bibr">13</xref>]. We therefore hypothesized that the loss of these BER/SSBR factors would impact the level of PARylation in replicating cells.</p><p>To test this, XRCC1, POLB, APTX, and LIG3 were knocked out in LN428 cells, and PAR levels in LN428/XRCC1-KO (Fig.&#160;<xref rid="F3" ref-type="fig">3A</xref>), LN428/POLB-KO (Fig.&#160;<xref rid="F3" ref-type="fig">3B</xref>), LN428/APTX-KO (Fig.&#160;<xref rid="F3" ref-type="fig">3C</xref>), and LN428/LIG3-KO (Fig.&#160;<xref rid="F3" ref-type="fig">3D</xref>) cells were analyzed upon NRH, PARGi, or NRH&#160;+&#160;PARGi exposure by immunoblot, as compared to a DMSO control and to the parental LN428 cells. Consistent with studies from us and others, endogenous PAR levels are drastically enhanced upon PARGi or NRH&#160;+&#160;PARGi treatment in the BER/SSBR-depleted cells, as compared to the parental LN428 cells. To validate this finding and to demonstrate the cell line independence of PARylation suppression by XRCC1, POLB, APTX, and LIG3, these BER/SSBR factors were also knocked out in the ES-2 cell line. Similarly, ES-2/XRCC1-KO (Fig.&#160;<xref rid="F3" ref-type="fig">3E</xref>), ES-2/POLB-KO (Fig.&#160;<xref rid="F3" ref-type="fig">3F</xref>), ES-2/APTX-KO (Fig.&#160;<xref rid="F3" ref-type="fig">3G</xref>), and ES-2/LIG3-KO (Fig.&#160;<xref rid="F3" ref-type="fig">3H</xref>) cells exposed to PARGi or NRH + PARGi showed enhanced PARylation compared with the parental ES-2 cells. Conversely, no increase in PAR is observed in APE1-KO cells exposed to NRH + PARGi (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2</xref>). Overall, these studies validate that XRCC1, POLB, APTX, and LIG3 each contribute to the suppression of endogenous PARylation in response to replication stress, revealed by PARG inhibition.</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>BER/SSBR factors XRCC1, POLB, APTX, and LIG3 regulate PARylation in response to replication stress. Immunoblot of (<bold>A</bold>) LN428 and LN428/XRCC1-KO, (<bold>B</bold>) LN428 and LN428/POLB-KO, (<bold>C</bold>) LN428 and LN428/APTX-KO, (<bold>D</bold>) LN428 and LN428/LIG3-KO, (<bold>E</bold>) ES-2 and ES-2/XRCC1-KO, (<bold>F</bold>) ES-2 and ES-2/POLB-KO, (<bold>G</bold>) ES-2 and ES-2/APTX-KO, and (<bold>H</bold>) ES-2 and ES-2/LIG3-KO whole cell lysates. Blots on the left show the respective knockout of XRCC1, POLB, APTX, or LIG3. The blots on the right show the comparative analysis of replication-dependent PAR formation following 8 h exposure of cells to vehicle (DMSO), NRH (100 &#956;M), PARGi (PDD00017273, 10 &#181;M), or NRH + PARGi. &#946;-ACTIN or H3 was used as a loading control.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="zcaf057fig3.jpg"/></fig></sec><sec id="SEC3-20"><title>Depletion of XRCC1, POLB, APTX, and LIG3 overcomes PARP inhibitor resistance</title><p>The elevated level of PARP1/PARP2 activation in the LN428 and ES-2 cells depleted of the BER/SSBR scaffold protein XRCC1, and of the BER/SSBR factors POLB, APTX, and LIG3, suggests the accumulation of PARP1/PARP2 substrates such as single-stranded DNA gaps [<xref rid="B46" ref-type="bibr">46</xref>] that may arise from Okazaki fragment processing defects [<xref rid="B67" ref-type="bibr">67</xref>]. As single-stranded DNA gaps are suggested to be a major indicator of PARP-inhibitor responsiveness [<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B112" ref-type="bibr">112</xref>], we next evaluated if loss of these BER factors increased cellular sensitivity to a panel of PARP1/PARP2 inhibitors.</p><p>The cell-killing efficacy of PARP inhibitors was found to be associated with the ability of the inhibitor to trap the enzymes (PARP1/PARP2) at the site of DNA damage [<xref rid="B113" ref-type="bibr">113</xref>]. It was then determined that homologous recombination enzymes, as well as numerous additional DNA repair enzymes, are involved in the repair of the trapped PARP1/PARP2-DNA complex, including POLB and FEN1, among other DDR pathway proteins [<xref rid="B113" ref-type="bibr">113</xref>]. We therefore tested a panel of PARP1/PARP2 inhibitors (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S3A</xref>), with varying degrees of efficacy and specificity. Based on the mechanism of action and repair of these PARP-trappers [<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B114" ref-type="bibr">114</xref>], we evaluated the response of each compound following exposure to the LN428 and ES-2 parental cells and the corresponding XRCC1-KO cells (Fig.&#160;<xref rid="F4" ref-type="fig">4A</xref>&#8211;<xref rid="F4" ref-type="fig">D</xref> and Supplementary Fig.&#160;<xref rid="sup1" ref-type="supplementary-material">S3B</xref>&#8211;D). Of these, BMN-673 showed the strongest effect in the XRCC1-KO cells (Fig. <xref rid="F4" ref-type="fig">4B</xref> and&#160;<xref rid="F4" ref-type="fig">D</xref>), considered to be the strongest or most effective of the PARP-trappers [<xref rid="B114" ref-type="bibr">114</xref>].</p><fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p>BER/SSBR depletion overcomes PARPi resistance in glioblastoma and ovarian cancer cells. (<bold>A</bold>) Immunoblot for XRCC1 in LN428 and LN428/XRCC1-KO cells, with H3 used as a loading control. (<bold>B</bold>) Viable LN428 and LN428/XRCC1-KO cells (%) exposed to either ABT-888 or BMN-673. (<bold>C</bold>) Immunoblot for XRCC1 in ES-2 and ES-2/XRCC1-KO cells, with H3 used as a loading control. (<bold>D</bold>) Viable ES-2 and ES-2/XRCC1-KO cells (%) exposed to either ABT-888 or BMN-673. (<bold>E</bold>) Immunoblot for XRCC1 in PARP inhibitor-resistant C4-2 and C4-2/XRCC1-KO cells, with H3 used as a loading control. (<bold>F</bold>) Viable cells (%) in response to BMN-673 exposure: PEO1, C4-2, and C4-2/XRCC1-KO cells. (<bold>G</bold>) Immunoblot for POLB in C4-2 and C4-2/POLB-KO cells, with H3 used as a loading control. (<bold>H</bold>) Viable cells (%) in response to BMN-673 exposure: PEO1, C4-2, and C4-2/POLB-KO cells. (<bold>I</bold>) Immunoblot for APTX in C4-2 and C4-2/APTX-KO cells, with H3 used as a loading control. (<bold>J</bold>) Viable cells (%) in response to BMN-673 exposure: PEO1, C4-2, and C4-2/APTX-KO cells. (<bold>K</bold>) Immunoblot for LIG3 in C4-2 and C4-2/LIG-KO cells, with H3 used as a loading control. (<bold>L</bold>) Viable cells (%) in response to BMN-673 exposure: PEO1, C4-2, and C4-2/LIG3-KO cells. For panels (H), (J), and (L), the dotted lines were taken from panel (F) to simplify comparison between the knockouts and C4-2 and PEO1 cells. For panels (B), (D), (F), (H), (J), and (L), viability was assayed after 120 h of exposure to the indicated compounds.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="zcaf057fig4.jpg"/></fig><p>To expand our analysis, we selected PARP inhibitor-sensitive (BRCA2 mutated) PEO1 cells and PARP inhibitor-resistant (BRCA2 proficient) C4-2 cells. We treated both with the PARP inhibitor BMN-673 for 120 h (5 days) and confirmed that the PEO1 cells are sensitive to PARP inhibitors while the BRCA2-proficient C4-2 cells are resistant [<xref rid="B85" ref-type="bibr">85</xref>], as expected (Fig.&#160;<xref rid="F4" ref-type="fig">4F</xref>). To determine if loss of BER can overcome the resistance of C4-2 cells to PARP inhibition, XRCC1, POLB, APTX, and LIG3 were each knocked out via Cas9 gene editing. As shown, C4-2/XRCC1-KO (Fig. <xref rid="F4" ref-type="fig">4E</xref>), C4-2/POLB-KO (Fig.&#160;<xref rid="F4" ref-type="fig">4G</xref>), C4-2/APTX-KO (Fig.&#160;<xref rid="F4" ref-type="fig">4I</xref>), and C4-2/LIG3-KO (Fig.&#160;<xref rid="F4" ref-type="fig">4K</xref>) cells were exposed to the PARPi for 120 h (5 days). Like the enhanced sensitivity seen in the LN428/XRCC1-KO and ES-2/XRCC1-KO cells (Fig. <xref rid="F4" ref-type="fig">4B</xref> and&#160;<xref rid="F4" ref-type="fig">D</xref>), loss of XRCC1, POLB, APTX, or LIG3 each leads to an increase in PARPi sensitivity (Fig. <xref rid="F4" ref-type="fig">4F</xref>, <xref rid="F4" ref-type="fig">H</xref>, <xref rid="F4" ref-type="fig">J</xref>, and L), albeit to varying degrees.</p></sec><sec id="SEC3-21"><title>Depletion of XRCC1, POLB, APTX, or LIG3 overcomes PARGi resistance</title><p>In our previous studies, head and neck cancer cells, as well as GSCs, were resistant to PARGi-induced cell killing [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B75" ref-type="bibr">75</xref>]. However, each showed enhanced PARGi-induced PAR levels and increased PARGi-induced apoptotic cell death when POLB or XRCC1 was depleted. We therefore hypothesized that PARG inhibitor-resistant cell lines utilize the BER/SSBR proteins XRCC1, POLB, APTX, and LIG3 to suppress PARP1/PARP2-mediated PAR in response to replication stress, and therefore, depletion of BER/SSBR proteins should overcome PARGi resistance in the glioma and ovarian cell lines under study herein. To test this hypothesis, the PARGi-resistant cell lines LN428 and ES-2, and their XRCC1, POLB, APTX, and LIG3 knockout derivatives, were compared for the response to PARGi treatment. Consistent with our earlier studies, the LN428/XRCC1-KO (Fig.&#160;<xref rid="F5" ref-type="fig">5A</xref>), LN428/POLB-KO (Fig.&#160;<xref rid="F5" ref-type="fig">5B</xref>), LN428/APTX-KO (Fig.&#160;<xref rid="F5" ref-type="fig">5C</xref>), and LN428/LIG3-KO (Fig.&#160;<xref rid="F5" ref-type="fig">5D</xref>) cells showed enhanced response to increasing doses of PARGi. Next, caspase-3/7 activity, after 48 h, was evaluated in LN428 cells and the corresponding LN428/KO cells upon PARGi (10 &#956;M) treatment. In line with the cell-killing analyses (Fig. <xref rid="F5" ref-type="fig">5A</xref>&#8211;<xref rid="F5" ref-type="fig">D</xref>), cells with a loss of these BER/SSBR factors all showed an increase in PARGi-induced apoptosis (Fig. <xref rid="F5" ref-type="fig">5E</xref>&#8211;<xref rid="F5" ref-type="fig">H</xref>).</p><fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><p>BER/SSBR depletion overcomes PARGi resistance in glioblastoma and ovarian cancer cells. Viable cells (%) in response to PARGi (PDD00017273) in (<bold>A</bold>) LN428 and LN428/XRCC1-KO cells, (<bold>B</bold>) LN428 and LN428/POLB-KO cells, (<bold>C</bold>) LN428 and LN428/APTX-KO cells, or (<bold>D</bold>) LN428 and LN428/LIG3-KO cells. Cells (%) showing caspase-3/7<sup>+</sup> activity in response to PARGi (PDD00017273) in (<bold>E</bold>) LN428 and LN428/XRCC1-KO cells, (<bold>F</bold>) LN428 and LN428/POLB-KO cells, (<bold>G</bold>) LN428 and LN428/APTX-KO cells, or (<bold>H</bold>) LN428 and LN428/LIG3-KO cells. Viable cells (%) in response to PARGi (PDD00017273) in (<bold>I</bold>) ES-2 and ES-2/XRCC1-KO cells, (<bold>J</bold>) ES-2 and ES-2/POLB-KO cells, (<bold>K</bold>) ES-2 and ES-2/APTX-KO cells, or (<bold>L</bold>) ES-2 and ES-2/LIG3-KO cells. Cells (%) showing caspase-3/7<sup>+</sup> activity in response to PARGi (PDD00017273) in (<bold>M</bold>) ES-2 and ES-2/XRCC1-KO cells, (<bold>N</bold>) ES-2 and ES-2/POLB-KO cells, (<bold>O</bold>) ES-2 and ES-2/APTX-KO cells, or (<bold>P</bold>) ES-2 and ES-2/LIG3-KO cells. For the viability assays, viability was assayed after 120 h of exposure to the indicated compound, and for the caspase activation assays, the activation of caspase-3/7<sup>+</sup> was assayed 48 h after drug exposure. For panels (B), (C), and (D), the dotted line was taken from panel (A) to simplify the comparison between LN428 and the corresponding knockout cells. For panels (J), (K), and (L), the dotted line was taken from panel (I) to simplify the comparison between ES-2 and the corresponding knockout cells. Where indicated,&#160;<italic toggle="yes">P</italic>&lt;* .05,&#160;<italic toggle="yes">P</italic>&lt;** .01,&#160;<italic toggle="yes">P</italic>&lt;*** .001,&#160;<italic toggle="yes">P</italic>&lt;**** .0001; two-way ANOVA.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="zcaf057fig5.jpg"/></fig><p>To validate that the loss of XRCC1, POLB, APTX, and LIG3 can overcome PARGi resistance in a second cancer cell line, ES-2, ES-2/XRCC1-KO, ES-2/POLB-KO, ES-2/APTX-KO, and ES-2/LIG3-KO cells were exposed to increasing doses of PARGi. Compared to the non-responsive ES-2 cells, the ES-2/XRCC1-KO (Fig.&#160;<xref rid="F5" ref-type="fig">5I</xref>), ES-2/POLB-KO (Fig.&#160;<xref rid="F5" ref-type="fig">5J</xref>), ES-2/APTX-KO (Fig.&#160;<xref rid="F5" ref-type="fig">5K</xref>), and ES-2/LIG3-KO (Fig.&#160;<xref rid="F5" ref-type="fig">5L</xref>) cell lines were significantly more sensitive to PARGi treatment. In addition, these ES-2/KO cell lines showed significantly stronger activation of caspase-3/7 upon PARGi exposure (Fig. <xref rid="F5" ref-type="fig">5M</xref>&#8211;<xref rid="F5" ref-type="fig">P</xref>), like what was observed in the LN428 and LN428/KO cells (Fig. <xref rid="F5" ref-type="fig">5E</xref>&#8211;<xref rid="F5" ref-type="fig">H</xref>).</p></sec><sec id="SEC3-22"><title>BER/SSBR factor depletion activates the S-phase checkpoint and enhances PARGi-induced and ATRi-induced replication catastrophe</title><p>PARG inhibitor sensitivity correlates with the activation of the S-phase checkpoint [<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B73" ref-type="bibr">73</xref>]. In that regard, we previously found that in head &amp; neck cancer cells, POLB plays a crucial role in modulating the cellular response to PARG inhibition, highlighting POLB-dependent phosphorylation of KAP1, RPA2, and CHK1 [<xref rid="B75" ref-type="bibr">75</xref>]. We therefore hypothesized that depletion of the BER/SSBR factors XRCC1, POLB, APTX, and LIG3 would further increase replication stress to activate ATR and the S-phase checkpoint. In line with this hypothesis, PARGi treatment showed ATR-dependent phosphorylation of CHK1, on S345 (Fig. <xref rid="F6" ref-type="fig">6A</xref> and Supplementary Fig. <xref rid="sup1" ref-type="supplementary-material">S4A</xref>), as well as on S317 (Fig.&#160;<xref rid="F6" ref-type="fig">6A</xref>), in an XRCC1-regulated manner in ES-2 cells. Further, NRH&#160;+&#160;PARGi treatment of LN428 cells induced ATR-dependent phosphorylation of CHK1 (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S4B</xref>). In all cases, activation of pCHK1, as measured by phosphorylation on residue S345, also revealed a minor dependence on ATM &amp; DNA-PK (Fig. <xref rid="F6" ref-type="fig">6A</xref> and Supplementary Fig.&#160;<xref rid="sup1" ref-type="supplementary-material">S4A</xref> and <xref rid="sup1" ref-type="supplementary-material">B</xref>).</p><fig position="float" id="F6" orientation="portrait"><label>Figure 6.</label><caption><p>Targeting the S-phase checkpoint overcomes PARGi resistance in glioblastoma and ovarian cancer cells. (<bold>A</bold>) Immunoblot of ES-2/XRCC1-KO whole cell extracts for pCHK1(S345), pCHK1(S317), and CHK1, with H3 used as a loading control. The induction factor (I.F.) for CHK1 phosphorylation was determined by densitometry analysis and is listed under each lane. Cells were exposed to vehicle control (DMSO), ATRi (AZD6738, 10 &#181;M), ATMi (KU-55933, 10 &#181;M), DNA-PKi (KU-57788, 10 &#181;M), and/or PARGi (PDD00017273, 10 &#181;M) as indicated, for 24 h. (<bold>B</bold>) Immunoblot of ES-2 and ES-2/XRCC1-KO whole cell extracts for pRPA2 (S4/S8), RPA2, pCHK1 (S345), CHK1, pKAP1 (S824), and KAP1, with H3 used as a loading control. Cells were exposed to PARGi (PDD00017273, 5 &#181;M) for the indicated time points, with DMSO as the vehicle control. (<bold>C</bold>) Quantification of PAR (green), pRPA(S4/S8) (red), and PAR/pRPA(S4/S8) co-localized (black) foci. Where indicated, <italic toggle="yes">P</italic>&lt;* .05, <italic toggle="yes">P</italic>&lt;** .01,&#160;<italic toggle="yes">P</italic>&lt;***.001, <italic toggle="yes">P</italic>&lt; ****.0001; Student&#8217;s <italic toggle="yes">t</italic>-test (representative images in Supplementary Fig. S4C). (<bold>D</bold>) Immunoblot of ES-2/XRCC1-KO whole cell extracts for pKAP1 (S824) and KAP1, with H3 used as a loading control. Cells were exposed to vehicle control (DMSO), ATRi (AZD6738, 10 &#181;M), ATMi (KU-55933, 10 &#181;M), DNA-PKi (KU-57788, 10 &#181;M), and/or PARGi (PDD00017273, 10 &#181;M) as indicated for 24 h. (<bold>E</bold>) Immunoblot of ES-2/XRCC1-KO whole cell extracts for pKAP1 (S824) and KAP1, with H3 used as a loading control. <underline>Top</underline>: Cells were exposed to vehicle control (DMSO), ATMi (KU-55933, 10 &#181;M), DNA-PKi (KU-57788, 10 &#181;M), or ATMi + DNA-PKi, with or without PARGi (PDD00017273, 10 &#181;M) as indicated, for 24 h.&#160;<underline>Middle</underline>: Cells were exposed to vehicle control (DMSO), ATMi (KU-55933, 10 &#181;M), DNA-PKi (KU-57788, 10 &#181;M), or ATMi + DNA-PKi, with or without ATRi (AZD6738, 10 &#181;M) as indicated, for 24 h.&#160;<underline>Botttom</underline>: Cells were exposed to vehicle control (DMSO), ATMi (KU-55933, 10 &#181;M), DNA-PKi (KU-57788, 10 &#181;M), or ATMi + DNA-PKi, with or without ATRi (AZD6738, 10 &#181;M) + PARGi (PDD00017273, 10 &#181;M) as indicated, for 24 h.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="zcaf057fig6.jpg"/></fig><p>Given the enhanced PARGi-induced cell death (Fig.&#160;<xref rid="F5" ref-type="fig">5I</xref>), apoptosis (Fig.&#160;<xref rid="F5" ref-type="fig">5M</xref>), and CHK1 activation in the absence of XRCC1 (Fig. <xref rid="F6" ref-type="fig">6A</xref>), we compared the PARGi-induced replication checkpoint activation in ES-2 versus ES-2/XRCC1-KO cells (Fig.&#160;<xref rid="F6" ref-type="fig">6B</xref>). Consistent with the likely increase in single-stranded DNA gaps [<xref rid="B46" ref-type="bibr">46</xref>] and a possible defect in Okazaki fragment processing [<xref rid="B67" ref-type="bibr">67</xref>] in the absence of XRCC1, there is an elevated level of phosphorylated RPA2 (S4/S8) in the absence of XRCC1 that is further elevated upon PARGi treatment, as compared to the parental ES-2 cells (Fig. <xref rid="F6" ref-type="fig">6B</xref>). We also found significant co-localization of PAR and pRPA(S4/6) foci in response to PARGi + NRH treatment that is also XRCC1-dependent (Fig. <xref rid="F6" ref-type="fig">6C</xref> and Supplementary Fig.&#160;<xref rid="sup1" ref-type="supplementary-material">S4C</xref>).</p><p>Further, in addition to the observed increase in phosphorylated CHK1, we found that the most prominent BER/SSBR-dependent, PARGi-induced, checkpoint signal is the phosphorylation of KAP1 on S824 (Fig.&#160;<xref rid="F6" ref-type="fig">6B</xref>). Given that KAP1 is reported to be phosphorylated in an ATM-dependent manner, we evaluated the impact of PARGi-induced and ATRi-induced phosphorylation of KAP1 on S824, alone and following inhibition of the DDR kinases ATM and DNA-PK in the ES-2/XRCC1-KO cells (Fig. <xref rid="F6" ref-type="fig">6D</xref> and&#160;<xref rid="F6" ref-type="fig">E</xref>). Interestingly, ATRi alone, PARGi alone, or ATRi + PARGi gave rise to a strong level of KAP1 phosphorylation with suppression of the signal when combined with ATMi, DNA-PKi, or both (Fig. <xref rid="F6" ref-type="fig">6D</xref> and&#160;<xref rid="F6" ref-type="fig">E</xref>), suggestive of BER/SSBR regulation of PARGi-induced and ATRi-induced replication catastrophe&#160;[<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B115" ref-type="bibr">115</xref>].</p><p>Since both PARG and ATR inhibition lead to elevated KAP1 phosphorylation, suggestive of replication catastrophe, we anticipated that a combination of ATR and PARG inhibition would lead to an enhanced cell-killing effect. As shown, in both LN428 and C4-2 cells, there was a minor cell-killing effect upon exposure to ATRi (AZD6738), CHK1i (MK8776), or PARGi (PDD00017273) as a single agent (Fig. <xref rid="F7" ref-type="fig">7A</xref>&#8211;<xref rid="F7" ref-type="fig">D</xref>). However, when the CHK1i or the ATRi was combined with the PARGi, we observed a significantly enhanced response (Fig. <xref rid="F7" ref-type="fig">7A</xref>&#8211;<xref rid="F7" ref-type="fig">D</xref>, red lines).</p><fig position="float" id="F7" orientation="portrait"><label>Figure 7.</label><caption><p>PARGi response enhanced by co-inhibition with CHK1, ATR, and PRMT1i/PRMT5i. (<bold>A</bold>) Viable LN428 cells (%) in response to ATRi (AZD6738), PARGi (PDD00017273), and ATRi&#160;+&#160;PARGi (10 &#181;M) treatment. (<bold>B</bold>) Viable LN428 cells (%) in response to CHK1i (MK8776), PARGi (PDD00017273), and CHK1i + PARGi (10 &#181;M) treatment. The dotted line was taken from panel (A) for comparison. (<bold>C</bold>) Viable C4-2 cells (%) in response to ATRi (AZD6738), PARGi (PDD00017273), and ATRi&#160;+&#160;PARGi (10 &#181;M) treatment. (<bold>D</bold>) Viable C4-2 cells (%) in response to CHK1i (MK8776), PARGi (PDD00017273), and CHK1i + PARGi (10 &#181;M) treatment. The dotted line was taken from panel (C) for comparison. For panels (A&#8211;D), viable cells were assayed after 120 h of exposure to the indicated compounds. (<bold>E</bold>) Viable LN428 cells (%) in response to PARGi (PDD00017273) and PRMT1i (GSK336871) exposure at the indicated concentrations. (<bold>F</bold>) Viable LN428 cells (%) in response to PARGi (PDD00017273) and PRMT5i (PRT543) exposure at the indicated concentrations. The dotted line was taken from panel (E) for comparison. (<bold>G</bold>) Viable ES-2 cells (%) in response to PARGi (PDD00017273) and PRMT1i (GSK336871) exposure at the indicated concentrations. (<bold>H</bold>) Viable ES-2 cells (%) in response to PARGi (PDD00017273) and PRMT5i (PRT543) exposure at the indicated concentrations. The dotted line was taken from panel (G) for comparison. (<bold>I</bold>) Bliss synergy score for LN428 cells exposed to PARGi and PRMT1i, or PARGi and PRMT5i. (<bold>J</bold>) Bliss synergy score for ES-2 cells exposed to PARGi and PRMT1i, or PARGi and PRMT5i. (<bold>K</bold>) Model for the role of BER/SSBR in suppressing replication stress. Canonical and replication-associated BER/SSBR proteins process replication-stalling DNA lesions. Upon inhibition of BER by PARGi, the inter-S-phase checkpoint is activated via ATR/CHK1. Simultaneous inhibition of PARG and ATR/CHK1 causes cell death, and PRMT1/PRMT5 inhibition-induced cell death is synergistic with PARG inhibition [created in BioRender. Sobol, R. (2025) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com/xke5uat" ext-link-type="uri">https://BioRender.com/xke5uat</ext-link>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="zcaf057fig7.jpg"/></fig></sec><sec id="SEC3-23"><title>Enhanced PARG inhibitor cell sensitivity upon PRMT1/PRMT5 inhibition</title><p>Protein arginine methyltransferases (PRMTs) [<xref rid="B79" ref-type="bibr">79</xref>] modify arginine residues with a methyl group via asymmetric (PRMT1) and symmetric (PRMT5) dimethyl substitutions [<xref rid="B79" ref-type="bibr">79</xref>]. Primary targets of PRMTs include ATR, 53BP1, and BRCA1 [<xref rid="B79" ref-type="bibr">79</xref>], and they are suggested to impact the replication stress response [<xref rid="B82" ref-type="bibr">82</xref>]. Further, it has been proposed that the major impact of PRMT1 or PRMT5 inhibition is to suppress DNA repair gene expression [<xref rid="B116" ref-type="bibr">116</xref>&#8211;<xref rid="B118" ref-type="bibr">118</xref>], likely by impacting splicing [<xref rid="B119" ref-type="bibr">119</xref>]. Given the enhanced cell killing response observed when combining PARG inhibitors and ATR inhibitors (Fig. <xref rid="F7" ref-type="fig">7A</xref> and&#160;<xref rid="F7" ref-type="fig">C</xref>), and the proposed impact on ATR and the replication stress response by PRMT1 and PRMT5 inhibitors [<xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B117" ref-type="bibr">117</xref>, <xref rid="B119" ref-type="bibr">119</xref>], we evaluated the cellular response (LN428 cells and ES-2 cells) to PRMT1 and PRMT5 inhibitors alone, and when combined with sub-lethal doses of the PARG inhibitor PDD00017273 (10 &#956;M). [As shown in Fig. <xref rid="F5" ref-type="fig">5A</xref> and&#160;<xref rid="F5" ref-type="fig">I</xref>, there is &lt;5% cell killing when LN428 or ES-2 cells are treated with PDD00017273 at 10 &#956;M]. Both the LN428 cells (Fig. <xref rid="F7" ref-type="fig">7E</xref> and&#160;<xref rid="F7" ref-type="fig">F</xref>) and the ES-2 cells (Fig. <xref rid="F7" ref-type="fig">7G</xref> and&#160;<xref rid="F7" ref-type="fig">H</xref>) showed a synergistic response when PRMT1 or PRMT5 inhibitors were combined with PARG inhibitors (Fig. <xref rid="F7" ref-type="fig">7I</xref> and&#160;<xref rid="F7" ref-type="fig">J</xref>), with the strongest synergy observed in the ES-2 cells (Fig.&#160;<xref rid="F7" ref-type="fig">7J</xref>).</p><p>Overall, these studies suggest a model for the BER/SSBR response to PARP1/PARP2 activation in response to replication stress. As shown (Fig.&#160;<xref rid="F7" ref-type="fig">7K</xref>), the level of PAR induction is regulated by XRCC1 and the XRCC1-binding proteins POLB, APTX, and LIG3, which are further regulated by PARG, all to suppress the activation of the ATR/CHK1 S-phase checkpoint. The activation of the ATR/CHK1 checkpoint promotes survival, whereas PAR-induced cell killing is enhanced when ATR or CHK1 is inhibited. This might suggest a PARG/ATR functional relationship or may be related to a role for ATR inhibition in the induction of DNA damage, such as the recent demonstration that ATR inhibition leads to elevated genomic uracil [<xref rid="B120" ref-type="bibr">120</xref>], known to induce replication stress [<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B121" ref-type="bibr">121</xref>]. Further, given the regulatory control of ATR by the methylation transferases PRMT1 and PRMT5, this also suggests a synthetic lethal connectivity node between PARG and PRMT1/PRMT5 (Fig.&#160;<xref rid="F7" ref-type="fig">7K</xref>).</p></sec></sec><sec sec-type="discussion" id="SEC4"><title>Discussion</title><p>The vital importance of genome maintenance and the DDR is underscored by the multiple mechanisms that function to repair specific types or classes of damaged DNA [<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B123" ref-type="bibr">123</xref>]. Of these pathways, the signaling enzyme PARP1 [<xref rid="B124" ref-type="bibr">124</xref>], and in some cases PARP2 [<xref rid="B125" ref-type="bibr">125</xref>], are involved in the regulation or signaling for BER/SSBR [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B20" ref-type="bibr">20</xref>], MutS&#945; and MMR [<xref rid="B16" ref-type="bibr">16</xref>], and DDB2/XPC in NER-mediated UV damage repair [<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>], as well as TMEJ [<xref rid="B19" ref-type="bibr">19</xref>].</p><p>Our studies have focused on the activation of PARP1 and PARP2 and the central role these proteins play in the cellular response to DNA base damage to initiate canonical BER/SSBR [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B20" ref-type="bibr">20</xref>] (see Graphical Abstract). The resulting activation of PARP1/PARP2 leads to the synthesis of PAR at the site of the genomic insult, forming a scaffold for protein complex assembly to respond to the damage [<xref rid="B2" ref-type="bibr">2</xref>] via protein-encoded PAR binding domains [<xref rid="B15" ref-type="bibr">15</xref>]. Canonical BER/SSBR responds to base damage or SSBs in all phases of the cell cycle, primarily via DNA glycosylase-mediated lesion hydrolysis and/or APE1-induced or DNA damage-induced strand cleavage followed by PARP1/PARP2 activation, facilitating the recruitment of the end- and gap-processing proteins XRCC1, POLB, APTX, and LIG3. Once repair is complete, the damage signal (PAR) is removed by the PAR-degrading enzymes PARG, TARG1, and ARH3 [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>] (see Graphical Abstract). The requirement for these BER/SSBR proteins is demonstrated by loss or inhibition: BER/SSBR protein deficiency or inhibition leads to DNA damage-induced PAR accumulation and a block to glycolysis [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>] or initiation of G2/M arrest [<xref rid="B31" ref-type="bibr">31</xref>], depending on the damage type and extent.</p><p>Here, we expand our analysis to the activation of PARP1 and PARP2 in response to replication stress to initiate what may be called replication-associated BER/SSBR [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. We find that replication-dependent PARP1/PARP2 activation and recruitment of XRCC1 and select BER/SSBR factors are essential to suppress replication-stress-mediated PAR accumulation, CHK1 activation [<xref rid="B56" ref-type="bibr">56</xref>], and S-phase arrest [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>] (see Graphical Abstract). The replication-dependent or replication-stress-dependent substrates of PARP1, as well as PARP2, are varied, including BER/SSBR intermediates [<xref rid="B110" ref-type="bibr">110</xref>, <xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B126" ref-type="bibr">126</xref>], Okazaki fragments [<xref rid="B67" ref-type="bibr">67</xref>], single-stranded DNA gaps [<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B127" ref-type="bibr">127</xref>], nicks from the repair of misincorporated uracil or from abasic site repair [<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B120" ref-type="bibr">120</xref>, <xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B129" ref-type="bibr">129</xref>], stressed replication forks [<xref rid="B130" ref-type="bibr">130</xref>], and transcription-replication conflicts and R-loops [<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B131" ref-type="bibr">131</xref>]. In line with these findings, we find that PAR accumulates in a replication-dependent manner that is dependent on the expression of both PARP1 and PARP2 (Fig.&#160;<xref rid="F1" ref-type="fig">1</xref>). A role for PARP1 during replication has long been suggested [<xref rid="B132" ref-type="bibr">132</xref>] as PARP1 was identified as part of a multiprotein DNA replication complex [<xref rid="B133" ref-type="bibr">133</xref>] that includes DNA polymerase alpha-primase [<xref rid="B134" ref-type="bibr">134</xref>]. PARP1 has also been described as a sensor for Okazaki fragment processing [<xref rid="B67" ref-type="bibr">67</xref>], interacts with structures mimicking the replication fork [<xref rid="B107" ref-type="bibr">107</xref>], and signals to RECQ1 to suppress replication restart [<xref rid="B135" ref-type="bibr">135</xref>]. Further, it was recently found that PARP1 interacts with several additional replication factors, including TIMELESS and TIPIN, DNA translocases, ORC2, and TPX2 [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B130" ref-type="bibr">130</xref>, <xref rid="B131" ref-type="bibr">131</xref>, <xref rid="B136" ref-type="bibr">136</xref>]. Here we show that both PARP1 and PARP2 give rise to replication-dependent PAR synthesis (Fig.&#160;<xref rid="F1" ref-type="fig">1</xref>), similar to the combined role of both isoforms in DNA damage-induced PAR synthesis [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B137" ref-type="bibr">137</xref>].</p><p>In addition, similar to our findings in GSCs [<xref rid="B31" ref-type="bibr">31</xref>], the replication-dependent accumulation of PAR in these glioma (LN428) and ovarian (ES-2) cancer cell lines is enhanced upon supplementation with NRH, an NAD<sup>+</sup>-precursor that, when added to cells, can promote as much as a 10-fold increase in nuclear NAD<sup>+</sup> levels, enhancing PARP1/PARP2 activation potential [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B83" ref-type="bibr">83</xref>]. Consistent with our earlier report on GSCs [<xref rid="B31" ref-type="bibr">31</xref>], arrested LN428 or ES-2 cells show very little PAR accumulation (Fig.&#160;<xref rid="F1" ref-type="fig">1</xref>). In the absence of PAR, little to no BER/SSBR factor recruitment is expected [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. Conversely, replication-dependent PAR synthesis should facilitate the recruitment of the PAR-binding protein XRCC1 and the associated BER/SSBR factors that bind to XRCC1, including POLB, APTX, and LIG3 [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B138" ref-type="bibr">138</xref>].</p><p>To address whether activated PARP1 recruits BER proteins during replication in cancer cells, we developed both a two-vector and a single-vector PARP1/XRCC1 Split-TurboID system, expressed in LN428 and ES-2 cells (Fig.&#160;<xref rid="F2" ref-type="fig">2</xref>). The TurboID system has the advantage of identifying interacting protein partners in cells, in a temporal manner, by proximity biotinylation [<xref rid="B96" ref-type="bibr">96</xref>, <xref rid="B109" ref-type="bibr">109</xref>]. Our PARP1&#8211;XRCC1/Split-TurboID approach has the added advantage of only labeling proximal protein partners with biotin when PARP1 is bound to XRCC1, upon formation of the PARP1&#8211;XRCC1 activated complex [<xref rid="B28" ref-type="bibr">28</xref>]. Like the recruitment of key BER/SSBR factors in response to laser-induced DNA damage [<xref rid="B13" ref-type="bibr">13</xref>], we find that replication, or replication-stress-dependent PARP1 activation promotes the recruitment of the BER/SSBR scaffold protein XRCC1 and the XRCC1 binding proteins POLB, APTX, and LIG3 (Fig. <xref rid="F2" ref-type="fig">2</xref>), as well as the replication factor RPA2 that may suggest these BER factors are involved in gap repair [<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B127" ref-type="bibr">127</xref>] or Okazaki fragment processing [<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B139" ref-type="bibr">139</xref>, <xref rid="B140" ref-type="bibr">140</xref>, <xref rid="B141" ref-type="bibr">141</xref>]. However, such activation does not recruit the upstream BER protein APE1, consistent with its role prior to PARP1 activation [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B20" ref-type="bibr">20</xref>]. Interestingly, the basal level of PARP1 and XRCC1 biotinylation we observed (Fig.&#160;<xref rid="F2" ref-type="fig">2</xref>) suggests there is a low level of PARP1/XRCC1 complex formation in the fraction of resting cells isolated. However, this PARP1/XRCC1 complex formation is only marginally suppressed by pretreatment with a PARP inhibitor (not shown). The extent of PARP inhibitor suppression of the overall levels of basal PARP1/XRCC1 biotinylation and whether this is due to overall oxidative damage or a low level of replication-dependent PARP1 activation in the minor fraction of cells not in G1 remains to be determined.</p><p>Cells with DNA repair defects, especially defects in HR, have elevated levels of PAR [<xref rid="B142" ref-type="bibr">142</xref>, <xref rid="B143" ref-type="bibr">143</xref>]. Similarly, loss of some BER factors increases spontaneous or DNA damage-induced PAR levels [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. This may be due to increased binding of PARP1 and PARP2 at sites of DNA damage [<xref rid="B13" ref-type="bibr">13</xref>] and/or persistence of PARP1/PARP2-activating repair intermediates [<xref rid="B110" ref-type="bibr">110</xref>, <xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B126" ref-type="bibr">126</xref>]. This would suggest that loss of some or all of the BER/SSBR proteins that are recruited to the activated PARP1/XRCC1 complex may lead to prolonged PARP activation or hyper-PARylation [<xref rid="B138" ref-type="bibr">138</xref>]. We tested this concept here by CRISPR/Cas9-mediated KO of XRCC1, APTX, POLB, or LIG3 in both the LN428 and ES-2 cells, as well as XRCC1-KO and APE1-KO in RPE-1 cells (Fig. <xref rid="F3" ref-type="fig">3</xref> and&#160;Supplementary Fig. <xref rid="sup1" ref-type="supplementary-material">S2</xref>). Consistent with a biological role for these BER/SSBR factors in replicating cells and in line with some earlier reports [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B110" ref-type="bibr">110</xref>], cells with loss of XRCC1, APTX, POLB, or LIG3, but not APE1, show elevated PAR levels when treated with a PARGi that is further enhanced when co-treated with the NAD<sup>+</sup>-precursor NRH (Fig. <xref rid="F3" ref-type="fig">3</xref> and&#160;Supplementary Fig. <xref rid="sup1" ref-type="supplementary-material">S2</xref>).</p><p>The increased PAR level, seen when some BER/SSBR factors are absent, has been suggested to impact PARP-inhibitor response since the expression of XRCC1 was shown to prevent PARP1 trapping [<xref rid="B110" ref-type="bibr">110</xref>] at the site of the damage, and its loss will enhance PARP1/PARP2 binding to the lesion site [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B110" ref-type="bibr">110</xref>]. This would imply that BER/SSBR defective cells may be hypersensitive to PARP-trapping agents [<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B114" ref-type="bibr">114</xref>]. To that end, we tested a panel of PARP inhibitors (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2</xref>) in the LN428 and ES-2 cells and the corresponding XRCC1-KO cells (Fig. <xref rid="F4" ref-type="fig">4</xref> and&#160;Supplementary Fig. <xref rid="sup1" ref-type="supplementary-material">S2</xref>). In line with a role for BER/SSBR in preventing PARP1 trapping [<xref rid="B110" ref-type="bibr">110</xref>], the most effective PARP inhibitor for XRCC1-KO cells (BMN-673) was previously shown to be the most effective of the PARP trappers [<xref rid="B114" ref-type="bibr">114</xref>]. We then expanded our analysis of BER/SSBR involvement in the cellular response to PARP inhibition by developing KOs of XRCC1, APTX, POLB, and LIG3 in C4-2 cells, a PARP-inhibitor-resistant (BRCA2 proficient) ovarian cancer cell line, and compared the response to PARP inhibitor-sensitive (BRCA2 mutated) PEO1 cells. Consistent with the increased PAR levels, the KO cells showed varying degrees of PARPi sensitivity (Fig.&#160;<xref rid="F4" ref-type="fig">4</xref>). Similarly, several earlier PARPi screens have reported a role for some BER/SSBR proteins in causing PARPi resistance, including POLB, XRCC1, and LIG3 [<xref rid="B144" ref-type="bibr">144</xref>&#8211;<xref rid="B148" ref-type="bibr">148</xref>]. Here, we expand this to also include the BER/SSBR factor APTX and show that each of these BER/SSBR factors (XRCC1, APTX, POLB, and LIG3) appears to suppress spontaneous replication-dependent PAR synthesis, and likely suppress PARP-trapping since they show sensitivity to the PARP-trapping agent BMN-673 (Fig.&#160;<xref rid="F4" ref-type="fig">4</xref>). Further, the elevated PAR levels, when a PARGi is combined with NRH, are another example of how NAD<sup>+</sup> enhances PARP1/PARP2 activation [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B83" ref-type="bibr">83</xref>].</p><p>Although the mechanism of PARGi sensitivity has yet to be completely defined, the elevated levels of replication-dependent PAR observed when BER/SSBR is defective (Fig.&#160;<xref rid="F4" ref-type="fig">4</xref>) also suggest a role for BER/SSBR in regulating or attenuating the cellular response to PARG inhibitors since unrestrained replication-dependent PAR can impact the S-phase replication checkpoint [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B78" ref-type="bibr">78</xref>]. Deletion of the gene for PARG in mice leads to early embryonic lethality and enhanced sensitivity to DNA-damaging agents [<xref rid="B149" ref-type="bibr">149</xref>] and, in human cells, is required for S-phase progression [<xref rid="B150" ref-type="bibr">150</xref>]. Further, PARG inhibitors have been shown to enhance the cellular response to temozolomide [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B151" ref-type="bibr">151</xref>] and to induce replication fork collapse [<xref rid="B76" ref-type="bibr">76</xref>], with increased response in BRCA2-defective cell lines [<xref rid="B152" ref-type="bibr">152</xref>]. Recently, we have suggested that the level of replication-dependent PAR correlates with PARG inhibitor sensitivity, demonstrating that enhanced PARylation, mediated by the NAD-boosting precursor NRH, significantly impacts the PARG inhibitor response [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. One possible mechanism offered to explain cell sensitivity to PARG inhibitors is the accumulation of reversed forks [<xref rid="B54" ref-type="bibr">54</xref>] or of single-strand DNA gaps during replication [<xref rid="B46" ref-type="bibr">46</xref>], the latter similar to recent models for PARP-inhibitor sensitivity [<xref rid="B44" ref-type="bibr">44</xref>]. Here, we also find that the BER/SSBR factors XRCC1, APTX, POLB, and LIG3 provide varying degrees of resistance to the model PARG inhibitor PDD00017273 (Fig.&#160;<xref rid="F5" ref-type="fig">5</xref>). The mechanistic explanation for the varied response is forthcoming in future studies, but may be related to possible unique roles that each play in response to PARP1/PARP2 activation. For example, the scaffold protein XRCC1 is expected to have the strongest phenotype, as observed, since XRCC1 is essential to both BER and SSBR, and is required for the recruitment of APTX, POLB, and LIG3. Similarly, LIG3 should be involved in all downstream processes requiring a DNA ligase and is likely involved in suppressing single-strand DNA gaps during replication, likely during repair of Okazaki fragments [<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B139" ref-type="bibr">139</xref>, <xref rid="B141" ref-type="bibr">141</xref>]. The precise role for APTX and POLB in suppressing PARP1/PARP2 activation during replication remains to be determined. However, as suggested earlier, suppression of POLB levels shows increased sensitivity to PARG inhibitors in head and neck cancer cells and cells with mutant IDH1 [<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B77" ref-type="bibr">77</xref>], and it is consistent with the apparent synthetic lethality between PARG and the BER/SSBR factor FEN-1 [<xref rid="B153" ref-type="bibr">153</xref>], so it may be feasible that POLB plays a backup role in Okazaki fragment processing.</p><p>Cell death mediated by unrepaired, replication-induced PAR is thought to be attenuated by ATR/CHK1 activation and initiation of the S-phase checkpoint [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B75" ref-type="bibr">75</xref>]. Here too, we find that PARGi-induced CHK1 phosphorylation is ATR dependent, with only a minor impact by ATM or DNA-PK inhibition (Fig.&#160;<xref rid="F6" ref-type="fig">6</xref>). Further, the activation of the ATR/CHK1 checkpoint is protective, since inhibitors to either ATR or CHK1 enhanced the cellular response to PARG inhibitors (Fig.&#160;<xref rid="F7" ref-type="fig">7</xref>), as we found in head and neck cancer cells [<xref rid="B75" ref-type="bibr">75</xref>]. As mentioned earlier, the enhanced response when PARG inhibitors are combined with ATR inhibitors may also be the result of elevated uracil, a BER substrate. Recently, it was shown that ATR inhibition leads to a rapid increase in genomic DNA contamination with uracil [<xref rid="B154" ref-type="bibr">154</xref>]. Given that genomic uracil induces replication stress [<xref rid="B121" ref-type="bibr">121</xref>] and can contribute to PAR-induced replication catastrophe [<xref rid="B57" ref-type="bibr">57</xref>], the enhanced response to PARGi, when combined with ATRi, may also be a result of elevated repair intermediates and PARP hyperactivation. However, the enhanced sensitivity of the BER/SSBR defective cells to PARG inhibition appears to give rise to ATM/DNA-PK-mediated phosphorylation of the transcriptional regulator KAP1 [<xref rid="B155" ref-type="bibr">155</xref>]. While KAP1 is phosphorylated by CHK1 on S473 [<xref rid="B156" ref-type="bibr">156</xref>], phosphorylation of KAP1 on S824, as evaluated here, is ATM dependent [<xref rid="B157" ref-type="bibr">157</xref>]. This may suggest that BER/SSBR impacts PARG inhibitor-induced accumulation of lesions that trigger replication catastrophe, leading to ATM and DNA-PK activation, and phosphorylation of KAP1 (Fig.&#160;<xref rid="F6" ref-type="fig">6</xref>). This would be consistent with BER/SSBR loss leading to an increase in single-strand DNA gaps during replication that translate to enhanced sensitivity to PARG inhibitors and an increase in DNA double-strand breaks and collapsed replication forks.</p><p>Both PARP inhibitors and PARG inhibitors are thought to target cells due to an accumulation of single-strand DNA gaps during replication [<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B54" ref-type="bibr">54</xref>], among other mechanisms [<xref rid="B112" ref-type="bibr">112</xref>]. Here, we show that cells with BER/SSBR defects in XRCC1, APTX, POLB, and LIG3 are sensitive to both the PARPi BMN-673 and the model PARGi PDD00017273 (Figs&#160;<xref rid="F4" ref-type="fig">4</xref> and&#160;<xref rid="F5" ref-type="fig">5</xref>), supportive of a common mechanism of sensitivity when BER/SSBR is defective. Further, we and others find that PARG inhibitors are synthetically lethal with ATR or CHK1 inhibitors [<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B78" ref-type="bibr">78</xref>], which is also seen with PARP inhibitors [<xref rid="B158" ref-type="bibr">158</xref>, <xref rid="B159" ref-type="bibr">159</xref>]. It is reasonable to suggest that defects in BER/SSBR factors, as shown here, lead to elevated strand breaks and the accumulation of single-strand DNA gaps during replication.</p><p>PRMT1/PRMT5 inhibitors synergize with PARP inhibitors in HR-proficient cells [<xref rid="B80" ref-type="bibr">80</xref>&#8211;<xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B116" ref-type="bibr">116</xref>], and so we expanded on the enhanced cell killing when combining PARGi and ATRi (Fig.&#160;<xref rid="F7" ref-type="fig">7</xref>). We next evaluated the impact of PARGi response in combination with either a PRMT1 or a PRMT5 inhibitor (Fig.&#160;<xref rid="F7" ref-type="fig">7</xref>). Inhibition of PRMT1 or PRMT5 induces DNA damage and is shown to down-regulate the expression of several DDR genes [<xref rid="B116" ref-type="bibr">116</xref>], including suppressing ATR levels and suppressing ATR activation [<xref rid="B82" ref-type="bibr">82</xref>], both of which would likely contribute to an enhanced response to PARG inhibition. In support of this hypothesis, we show that there is a strong synergy between PARG inhibitors and PRMT1/PRMT5 inhibitors, albeit to a greater extent in ES-2 cells (Fig.&#160;<xref rid="F7" ref-type="fig">7</xref>).</p><p>Collectively, we suggest a model whereby BER/SSBR regulates the accumulation of replication-stress-induced PAR signaling that leads to activation of the S-phase checkpoint, with both the ATR/CHK1 and PRMT1/PRMT5 signaling nodes providing a level of cellular protection. However, when PAR degradation is blocked by PARG inhibition, cells are hypersensitive to further inhibition of the PRMT1/PRMT5/ATR axis (Fig.&#160;<xref rid="F7" ref-type="fig">7K</xref>), highlighting potential biomarkers of PARG inhibitor response that may be explored to enhance the response to this new class of cancer treatments that impact PAR dynamics.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>zcaf057_Supplemental_File</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zcaf057_supplemental_file.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><title>Acknowledgements</title><p>The authors would like to thank Drs Abu-Bakr Al-Mehdi, Wito Richter, Aishwarya Prakash, Simon Grelet, Jianfeng Li, Anusha Angajala, and Natalie Gassman, as well as Alison Beiser (University of South Alabama), for suggestions during the initial part of this project. Also, we would like to thank the members of the Sobol Lab at Brown University for helpful data discussions and for keeping the lab supplied (Dan Ivanov), and also thanks to members of the Mani Lab (Brown University) for advice. The purchase and maintenance of the Nikon Ti2-E inverted confocal microscope with Ax-R in our lab at Brown University was provided by generous support from the Dr Robert Browning Foundation.</p><p>
<italic toggle="yes">Author contributions</italic>: Md Ibrahim (Data curation [equal], Formal analysis [equal], Investigation [equal], Methodology [equal], Resources [equal], Visualization [equal], Writing&#8212;original draft [equal], Writing&#8212;review &amp; editing [supporting]), Wynand P. Roos (Data curation [supporting], Formal analysis [supporting], Investigation [lead], Methodology [supporting], Resources [supporting], Validation [supporting], Visualization [supporting], Writing&#8212;original draft [supporting], Writing&#8212;review &amp; editing [supporting]), Jacob C. Schwartz (Formal analysis [supporting], Investigation [supporting], Writing&#8212;review &amp; editing [supporting]), Md Maruf Khan (Formal analysis [supporting], Investigation [supporting], Validation [supporting], Writing&#8212;review &amp; editing [supporting]), Rasha Q. Al-Rahahleh (Methodology [supporting], Writing&#8212;review &amp; editing [supporting]), Libby A. Beers (Formal analysis [supporting], Investigation [supporting], Writing&#8212;review &amp; editing [supporting]), Charlotte R. Pearson (Formal analysis [supporting], Investigation [supporting], Methodology [supporting], Writing&#8212;review &amp; editing [supporting]), Kahrie T. Langham (Formal analysis [supporting], Investigation [supporting], Writing&#8212;review &amp; editing [supporting]), Louis Boyang (Formal analysis [supporting], Investigation [supporting], Writing&#8212;review &amp; editing [supporting]), Jennifer Clark (Formal analysis [supporting], Investigation [supporting], Resources [supporting], Writing&#8212;review &amp; editing [supporting]), Faisal Hayat (Resources [supporting]), Qingming Fang (Methodology [supporting], Resources [supporting], Writing&#8212;review &amp; editing [supporting]), Christopher A. Koczor (Methodology [supporting], Resources [supporting], Writing&#8212;review &amp; editing [supporting]), Marie E. Migaud (Resources [supporting], Supervision [supporting], Writing&#8212;review &amp; editing [supporting]), and Robert W. Sobol (Conceptualization [lead], Data curation [equal], Formal analysis [equal], Funding acquisition [equal], Methodology [equal], Project administration [lead], Supervision [lead], Validation [equal], Visualization [equal], Writing&#8212;original draft [equal], Writing&#8212;review &amp; editing [lead]).</p></ack><sec sec-type="supplementary-material" id="SEC6"><title>Supplementary data</title><p>
<xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> is available at NAR Cancer online.</p></sec><sec id="SEC8"><title>Funding</title><p>Research in the Sobol lab on DNA repair, the analysis of DNA damage, and the impact of genotoxic exposure &amp; replication stress is funded by grants from the NIH [ES029518, ES028949, CA238061, CA236911, AG069740, and ES032522] and from the NSF [NSF-1841811]. Support was also provided by the Legoretta Cancer Center Endowment Fund (to R.W.S.) and was provided by grants from the Breast Cancer Research Foundation of Alabama, from the Abraham A. Mitchell Distinguished Investigator Fund, from the Mitchell Cancer Institute Molecular &amp; Metabolic Oncology Program Development Fund, and from the Legoretta Cancer Center Endowment Fund (to R.W.S.).</p></sec><sec sec-type="data-availability" id="SEC9"><title>Data availability</title><p>The data underlying this article will be shared on reasonable request to the corresponding author.</p></sec><notes id="NT1"><title>Notes</title><p>Present address: Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA 95757, United States</p><p>Present address: Department of Biochemistry and Structural Biology, Greehey Children&#8217;s Cancer Research, UTHSCSA, San Antonio, TX 78229, United States</p></notes><ref-list id="REF1"><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hassa</surname> &#160;<given-names>PO</given-names></string-name>, <string-name name-style="western"><surname>Hottiger</surname> &#160;<given-names>MO</given-names></string-name></person-group>. <article-title>The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases</article-title>. <source>Front Biosci</source>. <year>2008</year>;<volume>13</volume>:<fpage>3046</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.2741/2909</pub-id>.<pub-id pub-id-type="pmid">17981777</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saville</surname> &#160;<given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wilk</surname> &#160;<given-names>A</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>NAD<sup>+</sup>-mediated regulation of mammalian base excision repair</article-title>. <source>DNA Repair (Amst)</source>. <year>2020</year>;<volume>93</volume>:<fpage>102930</fpage>. <pub-id pub-id-type="doi">10.1016/j.dnarep.2020.102930</pub-id>.<pub-id pub-id-type="pmid">33087267</pub-id><pub-id pub-id-type="pmcid">PMC7586641</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ueda</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hayaishi</surname> &#160;<given-names>O</given-names></string-name></person-group>. <article-title>ADP-ribosylation</article-title>. <source>Annu Rev Biochem</source>. <year>1985</year>;<volume>54</volume>:<fpage>73</fpage>&#8211;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.bi.54.070185.000445</pub-id>.<pub-id pub-id-type="pmid">3927821</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Corda</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Di&#160;Girolamo</surname> &#160;<given-names>M</given-names></string-name></person-group>. <article-title>Functional aspects of protein mono-ADP-ribosylation</article-title>. <source>EMBO J</source>. <year>2003</year>;<volume>22</volume>:<fpage>1953</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/emboj/cdg209</pub-id>.<pub-id pub-id-type="pmid">12727863</pub-id><pub-id pub-id-type="pmcid">PMC156081</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schreiber</surname> &#160;<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Dantzer</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ame</surname> &#160;<given-names>JC</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Poly(ADP-ribose): novel functions for an old molecule</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2006</year>;<volume>7</volume>:<fpage>517</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1038/nrm1963</pub-id>.<pub-id pub-id-type="pmid">16829982</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Langelier</surname> &#160;<given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Mirhasan</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gilbert</surname> &#160;<given-names>K</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PARP enzyme de novo synthesis of protein-free poly(ADP-ribose)</article-title>. <source>Mol Cell</source>. <year>2024</year>;<volume>84</volume>:<fpage>4758</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2024.10.024</pub-id>.<pub-id pub-id-type="pmid">39536748</pub-id><pub-id pub-id-type="pmcid">PMC11664634</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Demeny</surname> &#160;<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Virag</surname> &#160;<given-names>L</given-names></string-name></person-group>. <article-title>The PARP enzyme family and the hallmarks of cancer part 1</article-title>. <source>Cancers</source>. <year>2021</year>;<volume>13</volume>:<fpage>2042</fpage>.<pub-id pub-id-type="pmid">33922595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13092042</pub-id><pub-id pub-id-type="pmcid">PMC8122967</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kratz</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kelly</surname> &#160;<given-names>MR</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>A multi-scale map of protein assemblies in the DNA damage response</article-title>. <source>Cell Syst</source>. <year>2023</year>;<volume>14</volume>:<fpage>447</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">37220749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cels.2023.04.007</pub-id><pub-id pub-id-type="pmcid">PMC10330685</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fouquerel</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Sobol</surname> &#160;<given-names>RW</given-names></string-name></person-group>. <article-title>ARTD1 (PARP1) activation and NAD<sup>+</sup> in DNA repair and cell death</article-title>. <source>DNA Repair (Amst)</source>. <year>2014</year>;<volume>23</volume>:<fpage>27</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.dnarep.2014.09.004</pub-id>.<pub-id pub-id-type="pmid">25283336</pub-id><pub-id pub-id-type="pmcid">PMC4252787</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fouquerel</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Goellner</surname> &#160;<given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname> &#160;<given-names>Z</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>ARTD1/PARP1 negatively regulates glycolysis by inhibiting hexokinase 1 independent of NAD<sup>+</sup> depletion</article-title>. <source>Cell Rep</source>. <year>2014</year>;<volume>8</volume>:<fpage>1819</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2014.08.036</pub-id>.<pub-id pub-id-type="pmid">25220464</pub-id><pub-id pub-id-type="pmcid">PMC4177344</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ahel</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ahel</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Matsusaka</surname> &#160;<given-names>T</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins</article-title>. <source>Nature</source>. <year>2008</year>;<volume>451</volume>:<fpage>81</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/nature06420</pub-id>.<pub-id pub-id-type="pmid">18172500</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Vyas</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kassab</surname> &#160;<given-names>MA</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>The role of poly ADP-ribosylation in the first wave of DNA damage response</article-title>. <source>Nucleic Acids Res</source>. <year>2017</year>;<volume>45</volume>:<fpage>8129</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx565</pub-id>.<pub-id pub-id-type="pmid">28854736</pub-id><pub-id pub-id-type="pmcid">PMC5737498</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koczor</surname> &#160;<given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Saville</surname> &#160;<given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Andrews</surname> &#160;<given-names>JF</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Temporal dynamics of base excision/single-strand break repair protein complex assembly/disassembly are modulated by the PARP/NAD<sup>+</sup>/SIRT6 axis</article-title>. <source>Cell Rep</source>. <year>2021</year>;<volume>37</volume>:<fpage>109917</fpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2021.109917</pub-id>.<pub-id pub-id-type="pmid">34731617</pub-id><pub-id pub-id-type="pmcid">PMC8607749</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Al-Rahahleh</surname> &#160;<given-names>RQ</given-names></string-name>, <string-name name-style="western"><surname>Roos</surname> &#160;<given-names>WP</given-names></string-name>, <string-name name-style="western"><surname>Saville</surname> &#160;<given-names>KM</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Overexpression of the WWE domain of RNF146 modulates poly-(ADP)-ribose dynamics at sites of DNA damage</article-title>. <source>DNA Repair (Amst)</source>. <year>2025</year>;<volume>150</volume>:<fpage>103845</fpage>. <pub-id pub-id-type="doi">10.1016/j.dnarep.2025.103845</pub-id>.<pub-id pub-id-type="pmid">40403420</pub-id><pub-id pub-id-type="pmcid">PMC12320510</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Al-Rahahleh</surname> &#160;<given-names>RQ</given-names></string-name>, <string-name name-style="western"><surname>Sobol</surname> &#160;<given-names>RW</given-names></string-name></person-group>. <article-title>Poly-ADP-ribosylation dynamics, signaling, and analysis</article-title>. <source>Environ and Mol Mutagen</source>. <year>2024</year>;<volume>65</volume>:<fpage>315</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1002/em.22623</pub-id>.<pub-id pub-id-type="pmcid">PMC11604531</pub-id><pub-id pub-id-type="pmid">39221603</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kadyrov</surname> &#160;<given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Modrich</surname> &#160;<given-names>P</given-names></string-name></person-group>. <article-title>PARP-1 enhances the mismatch-dependence of 5'-directed excision in human mismatch repair <italic toggle="yes">in vitro</italic></article-title>. <source>DNA Repair (Amst)</source>. <year>2011</year>;<volume>10</volume>:<fpage>1145</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.dnarep.2011.08.012</pub-id>.<pub-id pub-id-type="pmid">21945626</pub-id><pub-id pub-id-type="pmcid">PMC3222275</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robu</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname> &#160;<given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Petitclerc</surname> &#160;<given-names>N</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2013</year>;<volume>110</volume>:<fpage>1658</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1209507110</pub-id>.<pub-id pub-id-type="pmid">23319653</pub-id><pub-id pub-id-type="pmcid">PMC3562836</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pines</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mullenders</surname> &#160;<given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>van&#160;Attikum</surname> &#160;<given-names>H</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Touching base with PARPs: moonlighting in the repair of UV lesions and double-strand breaks</article-title>. <source>Trends Biochem Sci</source>. <year>2013</year>;<volume>38</volume>:<fpage>321</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2013.03.002</pub-id>.<pub-id pub-id-type="pmid">23562323</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vekariya</surname> &#160;<given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Minakhin</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chandramouly</surname> &#160;<given-names>G</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PARG is essential for Pol&#952;-mediated DNA end-joining by removing repressive poly-ADP-ribose marks</article-title>. <source>Nat Commun</source>. <year>2024</year>;<volume>15</volume>:<fpage>5822</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-024-50158-7</pub-id>.<pub-id pub-id-type="pmid">38987289</pub-id><pub-id pub-id-type="pmcid">PMC11236980</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Almeida</surname> &#160;<given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Sobol</surname> &#160;<given-names>RW</given-names></string-name></person-group>. <article-title>A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification</article-title>. <source>DNA Repair (Amst)</source>. <year>2007</year>;<volume>6</volume>:<fpage>695</fpage>&#8211;<lpage>711</lpage>. <pub-id pub-id-type="doi">10.1016/j.dnarep.2007.01.009</pub-id>.<pub-id pub-id-type="pmid">17337257</pub-id><pub-id pub-id-type="pmcid">PMC1995033</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hanzlikova</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gittens</surname> &#160;<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Krejcikova</surname> &#160;<given-names>K</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin</article-title>. <source>Nucleic Acids Res</source>. <year>2017</year>;<volume>45</volume>:<fpage>2546</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">27965414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkw1246</pub-id><pub-id pub-id-type="pmcid">PMC5389470</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fisher</surname> &#160;<given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Hochegger</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Takeda</surname> &#160;<given-names>S</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase</article-title>. <source>Mol Cell Biol</source>. <year>2007</year>;<volume>27</volume>:<fpage>5597</fpage>&#8211;<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.02248-06</pub-id>.<pub-id pub-id-type="pmid">17548475</pub-id><pub-id pub-id-type="pmcid">PMC1952076</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Almeida</surname> &#160;<given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Andrews</surname> &#160;<given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Sobol</surname> &#160;<given-names>RW</given-names></string-name></person-group>. <article-title>AP endonuclease 1: biological updates and advances in activity analysis</article-title>. <source>Methods Enzymol</source>. <year>2024</year>;<volume>705</volume>:<fpage>347</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">39389669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.mie.2024.07.011</pub-id><pub-id pub-id-type="pmcid">PMC12553405</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Prasad</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dyrkheeva</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname> &#160;<given-names>J</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Mammalian base excision repair: functional partnership between PARP-1 and APE1 in AP-site repair</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>:<fpage>e0124269</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0124269</pub-id>.<pub-id pub-id-type="pmid">26020771</pub-id><pub-id pub-id-type="pmcid">PMC4447435</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sukhanova</surname> &#160;<given-names>MV</given-names></string-name>, <string-name name-style="western"><surname>Khodyreva</surname> &#160;<given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Lebedeva</surname> &#160;<given-names>NA</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Human base excision repair enzymes apurinic/apyrimidinic endonuclease1 (APE1), DNA polymerase beta and poly(ADP-ribose) polymerase 1: interplay between strand-displacement DNA synthesis and proofreading exonuclease activity</article-title>. <source>Nucleic Acids Res</source>. <year>2005</year>;<volume>33</volume>:<fpage>1222</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gki266</pub-id>.<pub-id pub-id-type="pmid">15731342</pub-id><pub-id pub-id-type="pmcid">PMC549570</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Soll</surname> &#160;<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Sobol</surname> &#160;<given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Mosammaparast</surname> &#160;<given-names>N</given-names></string-name></person-group>. <article-title>Regulation of DNA alkylation damage repair: lessons and therapeutic opportunities</article-title>. <source>Trends Biochem Sci</source>. <year>2017</year>;<volume>42</volume>:<fpage>206</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2016.10.001</pub-id>.<pub-id pub-id-type="pmid">27816326</pub-id><pub-id pub-id-type="pmcid">PMC5336464</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Svilar</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Goellner</surname> &#160;<given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Almeida</surname> &#160;<given-names>KH</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage</article-title>. <source>Antioxid Redox Signaling</source>. <year>2011</year>;<volume>14</volume>:<fpage>2491</fpage>&#8211;<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2010.3466</pub-id>.<pub-id pub-id-type="pmcid">PMC3096496</pub-id><pub-id pub-id-type="pmid">20649466</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>El-Khamisy</surname> &#160;<given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Masutani</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname> &#160;<given-names>H</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage</article-title>. <source>Nucleic Acids Res</source>. <year>2003</year>;<volume>31</volume>:<fpage>5526</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkg761</pub-id>.<pub-id pub-id-type="pmid">14500814</pub-id><pub-id pub-id-type="pmcid">PMC206461</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Campalans</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kortulewski</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Amouroux</surname> &#160;<given-names>R</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Distinct spatiotemporal patterns and PARP dependence of XRCC1 recruitment to single-strand break and base excision repair</article-title>. <source>Nucleic Acids Res</source>. <year>2013</year>;<volume>41</volume>:<fpage>3115</fpage>&#8211;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt025</pub-id>.<pub-id pub-id-type="pmid">23355608</pub-id><pub-id pub-id-type="pmcid">PMC3597691</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Koczor</surname> &#160;<given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Saville</surname> &#160;<given-names>KM</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Overcoming temozolomide resistance in glioblastoma via enhanced NAD<sup>+</sup> bioavailability and inhibition of poly-ADP-ribose glycohydrolase</article-title>. <source>Cancers</source>. <year>2022</year>;<volume>14</volume>:<fpage>3572</fpage>.<pub-id pub-id-type="pmid">35892832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14153572</pub-id><pub-id pub-id-type="pmcid">PMC9331395</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>K</surname> &#160;<given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Ibrahim</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>NAD<sup>+</sup> bioavailability mediates PARG inhibition-induced replication arrest, intra S-phase checkpoint and apoptosis in glioma stem cells</article-title>. <source>NAR Cancer</source>. <year>2021</year>;<volume>3</volume>:<fpage>zcab044</fpage>. <pub-id pub-id-type="doi">10.1093/narcan/zcab044</pub-id>.<pub-id pub-id-type="pmid">34806016</pub-id><pub-id pub-id-type="pmcid">PMC8600031</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname> &#160;<given-names>IK</given-names></string-name>, <string-name name-style="western"><surname>Stegeman</surname> &#160;<given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Brosey</surname> &#160;<given-names>CA</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>A quantitative assay reveals ligand specificity of the DNA scaffold repair protein XRCC1 and efficient disassembly of complexes of XRCC1 and the poly(ADP-ribose) polymerase 1 by poly(ADP-ribose) glycohydrolase</article-title>. <source>J Biol Chem</source>. <year>2015</year>;<volume>290</volume>:<fpage>3775</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.624718</pub-id>.<pub-id pub-id-type="pmid">25477519</pub-id><pub-id pub-id-type="pmcid">PMC4319041</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hanahan</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Weinberg</surname> &#160;<given-names>RA</given-names></string-name></person-group>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source>. <year>2011</year>;<volume>144</volume>:<fpage>646</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id>.<pub-id pub-id-type="pmid">21376230</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Berti</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cortez</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lopes</surname> &#160;<given-names>M</given-names></string-name></person-group>. <article-title>The plasticity of DNA replication forks in response to clinically relevant genotoxic stress</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2020</year>;<volume>21</volume>:<fpage>633</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-020-0257-5</pub-id>.<pub-id pub-id-type="pmid">32612242</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gaillard</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Garcia-Muse</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Aguilera</surname> &#160;<given-names>A</given-names></string-name></person-group>. <article-title>Replication stress and cancer</article-title>. <source>Nat Rev Cancer</source>. <year>2015</year>;<volume>15</volume>:<fpage>276</fpage>&#8211;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1038/nrc3916</pub-id>.<pub-id pub-id-type="pmid">25907220</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname> &#160;<given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Mirkin</surname> &#160;<given-names>SM</given-names></string-name></person-group>. <article-title>The balancing act of DNA repeat expansions</article-title>. <source>Curr Opin Genet Dev</source>. <year>2013</year>;<volume>23</volume>:<fpage>280</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.gde.2013.04.009</pub-id>.<pub-id pub-id-type="pmid">23725800</pub-id><pub-id pub-id-type="pmcid">PMC3703482</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Paeschke</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bochman</surname> &#160;<given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Garcia</surname> &#160;<given-names>PD</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Pif1 family helicases suppress genome instability at G-quadruplex motifs</article-title>. <source>Nature</source>. <year>2013</year>;<volume>497</volume>:<fpage>458</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1038/nature12149</pub-id>.<pub-id pub-id-type="pmid">23657261</pub-id><pub-id pub-id-type="pmcid">PMC3680789</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Primo</surname> &#160;<given-names>LMF</given-names></string-name>, <string-name name-style="western"><surname>Teixeira</surname> &#160;<given-names>LK</given-names></string-name></person-group>. <article-title>DNA replication stress: oncogenes in the spotlight</article-title>. <source>Genet Mol Biol</source>. <year>2019</year>;<volume>43</volume>:<fpage>e20190138</fpage>. <pub-id pub-id-type="doi">10.1590/1678-4685-gmb-2019-0138</pub-id>.<pub-id pub-id-type="pmid">31930281</pub-id><pub-id pub-id-type="pmcid">PMC7197996</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Poli</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tsaponina</surname> &#160;<given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Crabbe</surname> &#160;<given-names>L</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>dNTP pools determine fork progression and origin usage under replication stress</article-title>. <source>EMBO J</source>. <year>2012</year>;<volume>31</volume>:<fpage>883</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2011.470</pub-id>.<pub-id pub-id-type="pmid">22234185</pub-id><pub-id pub-id-type="pmcid">PMC3280562</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Helmrich</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ballarino</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tora</surname> &#160;<given-names>L</given-names></string-name></person-group>. <article-title>Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes</article-title>. <source>Mol Cell</source>. <year>2011</year>;<volume>44</volume>:<fpage>966</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2011.10.013</pub-id>.<pub-id pub-id-type="pmid">22195969</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Promonet</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Padioleau</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname> &#160;<given-names>Y</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Topoisomerase 1 prevents replication stress at R-loop-enriched transcription termination sites</article-title>. <source>Nat Commun</source>. <year>2020</year>;<volume>11</volume>:<fpage>3940</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-17858-2</pub-id>.<pub-id pub-id-type="pmid">32769985</pub-id><pub-id pub-id-type="pmcid">PMC7414224</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname> &#160;<given-names>B</given-names></string-name></person-group>. <article-title>Okazaki fragment maturation: nucleases take centre stage</article-title>. <source>J Mol Cell Biol</source>. <year>2011</year>;<volume>3</volume>:<fpage>23</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1093/jmcb/mjq048</pub-id>.<pub-id pub-id-type="pmid">21278448</pub-id><pub-id pub-id-type="pmcid">PMC3030970</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Panzarino</surname> &#160;<given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Krais</surname> &#160;<given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Cong</surname> &#160;<given-names>K</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Replication gaps underlie BRCA deficiency and therapy response</article-title>. <source>Cancer Res</source>. <year>2021</year>;<volume>81</volume>:<fpage>1388</fpage>&#8211;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-1602</pub-id>.<pub-id pub-id-type="pmid">33184108</pub-id><pub-id pub-id-type="pmcid">PMC8026497</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cong</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kousholt</surname> &#160;<given-names>AN</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency</article-title>. <source>Mol Cell</source>. <year>2021</year>;<volume>81</volume>:<fpage>3128</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2021.07.015</pub-id>.<pub-id pub-id-type="pmid">34216544</pub-id><pub-id pub-id-type="pmcid">PMC9089372</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bai</surname> &#160;<given-names>YR</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname> &#160;<given-names>WG</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname> &#160;<given-names>R</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>The recent advance and prospect of poly(ADP-ribose) polymerase inhibitors for the treatment of cancer</article-title>. <source>Med Res Rev</source>. <year>2025</year>;<volume>45</volume>:<fpage>214</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1002/med.22069</pub-id>.<pub-id pub-id-type="pmid">39180380</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ravindranathan</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Somuncu</surname> &#160;<given-names>O</given-names></string-name>, <string-name name-style="western"><surname>da&#160;Costa</surname> &#160;<given-names>A</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2024</year>;<volume>121</volume>:<fpage>e2413954121</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2413954121</pub-id>.<pub-id pub-id-type="pmid">39546575</pub-id><pub-id pub-id-type="pmcid">PMC11588084</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname> &#160;<given-names>SY</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>FANCM promotes PARP inhibitor resistance by minimizing ssDNA gap formation and counteracting resection inhibition</article-title>. <source>Cell Rep</source>. <year>2024</year>;<volume>43</volume>:<fpage>114464</fpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2024.114464</pub-id>.<pub-id pub-id-type="pmid">38985669</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gralewska</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gajek</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rybaczek</surname> &#160;<given-names>D</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>The influence of PARP, ATR, CHK1 inhibitors on premature mitotic entry and genomic instability in high-grade serous BRCA(MUT) and BRCA(WT) ovarian cancer cells</article-title>. <source>Cells</source>. <year>2022</year>;<volume>11</volume>:<fpage>1889</fpage>. <pub-id pub-id-type="doi">10.3390/cells11121889</pub-id> .<pub-id pub-id-type="pmid">35741017</pub-id><pub-id pub-id-type="pmcid">PMC9221516</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hewitt</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Borel</surname> &#160;<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Segura-Bayona</surname> &#160;<given-names>S</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD</article-title>. <source>Mol Cell</source>. <year>2021</year>;<volume>81</volume>:<fpage>767</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2020.12.006</pub-id>.<pub-id pub-id-type="pmid">33333017</pub-id><pub-id pub-id-type="pmcid">PMC7895907</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Slade</surname> &#160;<given-names>D</given-names></string-name></person-group>. <article-title>PARP and PARG inhibitors in cancer treatment</article-title>. <source>Genes Dev</source>. <year>2020</year>;<volume>34</volume>:<fpage>360</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1101/gad.334516.119</pub-id>.<pub-id pub-id-type="pmid">32029455</pub-id><pub-id pub-id-type="pmcid">PMC7050487</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ronson</surname> &#160;<given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Piberger</surname> &#160;<given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Higgs</surname> &#160;<given-names>MR</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation</article-title>. <source>Nat Commun</source>. <year>2018</year>;<volume>9</volume>:<fpage>746</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-03159-2</pub-id>.<pub-id pub-id-type="pmid">29467415</pub-id><pub-id pub-id-type="pmcid">PMC5821833</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>D&#8217;Andrea</surname> &#160;<given-names>AD</given-names></string-name></person-group>. <article-title>Mechanisms of PARP inhibitor sensitivity and resistance</article-title>. <source>DNA Repair (Amst)</source>. <year>2018</year>;<volume>71</volume>:<fpage>172</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.dnarep.2018.08.021</pub-id>.<pub-id pub-id-type="pmid">30177437</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carruthers</surname> &#160;<given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname> &#160;<given-names>SU</given-names></string-name>, <string-name name-style="western"><surname>Ramachandran</surname> &#160;<given-names>S</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Replication stress drives constitutive activation of the DNA damage response and radioresistance in glioblastoma stem-like cells</article-title>. <source>Cancer Res</source>. <year>2018</year>;<volume>78</volume>:<fpage>5060</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-0569</pub-id>.<pub-id pub-id-type="pmid">29976574</pub-id><pub-id pub-id-type="pmcid">PMC6128404</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ray&#160;Chaudhuri</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ahuja</surname> &#160;<given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Herrador</surname> &#160;<given-names>R</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Poly(ADP-ribosyl) glycohydrolase prevents the accumulation of unusual replication structures during unperturbed S phase</article-title>. <source>Mol Cell Biol</source>. <year>2015</year>;<volume>35</volume>:<fpage>856</fpage>&#8211;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.01077-14</pub-id>.<pub-id pub-id-type="pmid">25535335</pub-id><pub-id pub-id-type="pmcid">PMC4323491</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Illuzzi</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Fouquerel</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ame</surname> &#160;<given-names>JC</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PARG is dispensable for recovery from transient replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress</article-title>. <source>Nucleic Acids Res</source>. <year>2014</year>;<volume>42</volume>:<fpage>7776</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku505</pub-id>.<pub-id pub-id-type="pmid">24906880</pub-id><pub-id pub-id-type="pmcid">PMC4081103</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Min</surname> &#160;<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Bruhn</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Grigaravicius</surname> &#160;<given-names>P</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation</article-title>. <source>Nat Commun</source>. <year>2013</year>;<volume>4</volume>:<fpage>2993</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms3993</pub-id>.<pub-id pub-id-type="pmid">24356582</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ortega</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bournique</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Li</surname> &#160;<given-names>J</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Mechanism of DNA replication fork breakage and PARP1 hyperactivation during replication catastrophe</article-title>. <source>Sci Adv</source>. <year>2025</year>;<volume>11</volume>:<fpage>eadu0437</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.adu0437</pub-id>.<pub-id pub-id-type="pmid">40238882</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Laspata</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kaur</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mersaoui</surname> &#160;<given-names>SY</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PARP1 associates with R-loops to promote their resolution and genome stability</article-title>. <source>Nucleic Acids Res</source>. <year>2023</year>;<volume>51</volume>:<fpage>2215</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkad066</pub-id>.<pub-id pub-id-type="pmid">36794853</pub-id><pub-id pub-id-type="pmcid">PMC10018367</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schreuder</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wendel</surname> &#160;<given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Dorresteijn</surname> &#160;<given-names>CGV</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>(Single-stranded DNA) gaps in understanding BRCAness</article-title>. <source>Trends Genet</source>. <year>2024</year>;<volume>40</volume>:<fpage>757</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.tig.2024.04.013</pub-id>.<pub-id pub-id-type="pmid">38789375</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tirman</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Quinet</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells</article-title>. <source>Mol Cell</source>. <year>2021</year>;<volume>81</volume>:<fpage>4026</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2021.09.013</pub-id>.<pub-id pub-id-type="pmid">34624216</pub-id><pub-id pub-id-type="pmcid">PMC8555837</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wondisford</surname> &#160;<given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname> &#160;<given-names>R</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Deregulated DNA ADP-ribosylation impairs telomere replication</article-title>. <source>Nat Struct Mol Biol</source>. <year>2024</year>;<volume>31</volume>:<fpage>791</fpage>&#8211;<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1038/s41594-024-01279-6</pub-id>.<pub-id pub-id-type="pmid">38714889</pub-id><pub-id pub-id-type="pmcid">PMC11102865</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>De&#160;Rosa</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Barnes</surname> &#160;<given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Nyalapatla</surname> &#160;<given-names>PR</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>OGG1 and MUTYH repair activities promote telomeric 8-oxoguanine induced senescence in human fibroblasts</article-title>. <source>Nature communications</source>. <year>2025</year>;<volume>16</volume>:<fpage>893</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-024-55638-4</pub-id>.<pub-id pub-id-type="pmcid">PMC11751180</pub-id><pub-id pub-id-type="pmid">39837827</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Salvati</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Scarsella</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Porru</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy</article-title>. <source>Oncogene</source>. <year>2010</year>;<volume>29</volume>:<fpage>6280</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2010.344</pub-id>.<pub-id pub-id-type="pmid">20802516</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gaur</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bain</surname> &#160;<given-names>FE</given-names></string-name>, <string-name name-style="western"><surname>Meah</surname> &#160;<given-names>R</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Single-molecule analysis of PARP1-G-quadruplex interaction</article-title>. <comment>bioRxiv</comment>, <pub-id pub-id-type="doi">10.1101/2025.01.06.631587</pub-id>, <comment>8 January 2025, preprint: not peer reviewed</comment>.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Edwards</surname> &#160;<given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Marecki</surname> &#160;<given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Byrd</surname> &#160;<given-names>AK</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>G-quadruplex loops regulate PARP-1 enzymatic activation</article-title>. <source>Nucleic Acids Res</source>. <year>2021</year>;<volume>49</volume>:<fpage>416</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa1172</pub-id>.<pub-id pub-id-type="pmid">33313902</pub-id><pub-id pub-id-type="pmcid">PMC7797039</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zimmermann</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Murina</surname> &#160;<given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Reijns</surname> &#160;<given-names>MAM</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions</article-title>. <source>Nature</source>. <year>2018</year>;<volume>559</volume>:<fpage>285</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-018-0291-z</pub-id>.<pub-id pub-id-type="pmid">29973717</pub-id><pub-id pub-id-type="pmcid">PMC6071917</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hanzlikova</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kalasova</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Demin</surname> &#160;<given-names>AA</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>The importance of poly(ADP-Ribose) polymerase as a sensor of unligated Okazaki fragments during DNA replication</article-title>. <source>Mol Cell</source>. <year>2018</year>;<volume>71</volume>:<fpage>319</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2018.06.004</pub-id>.<pub-id pub-id-type="pmid">29983321</pub-id><pub-id pub-id-type="pmcid">PMC6060609</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bryant</surname> &#160;<given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Schultz</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname> &#160;<given-names>HD</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</article-title>. <source>Nature</source>. <year>2005</year>;<volume>434</volume>:<fpage>913</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nature03443</pub-id>.<pub-id pub-id-type="pmid">15829966</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Farmer</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>McCabe</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lord</surname> &#160;<given-names>CJ</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</article-title>. <source>Nature</source>. <year>2005</year>;<volume>434</volume>:<fpage>917</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1038/nature03445</pub-id>.<pub-id pub-id-type="pmid">15829967</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mortusewicz</surname> &#160;<given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Fouquerel</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ame</surname> &#160;<given-names>JC</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PARG is recruited to DNA damage sites through poly(ADP-ribose)- and PCNA-dependent mechanisms</article-title>. <source>Nucleic Acids Res</source>. <year>2011</year>;<volume>39</volume>:<fpage>5045</fpage>&#8211;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkr099</pub-id>.<pub-id pub-id-type="pmid">21398629</pub-id><pub-id pub-id-type="pmcid">PMC3130271</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaufmann</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Grishkovskaya</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Polyansky</surname> &#160;<given-names>AA</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>A novel non-canonical PIP-box mediates PARG interaction with PCNA</article-title>. <source>Nucleic Acids Res</source>. <year>2017</year>;<volume>45</volume>:<fpage>9741</fpage>&#8211;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx604</pub-id>.<pub-id pub-id-type="pmid">28934471</pub-id><pub-id pub-id-type="pmcid">PMC5766153</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Houl</surname> &#160;<given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Brosey</surname> &#160;<given-names>CA</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death</article-title>. <source>Nat Commun</source>. <year>2019</year>;<volume>10</volume>:<fpage>5654</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-13508-4</pub-id>.<pub-id pub-id-type="pmid">31827085</pub-id><pub-id pub-id-type="pmcid">PMC6906431</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pillay</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Brady</surname> &#160;<given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Dey</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy</article-title>. <source>Prog Biophys Mol Biol</source>. <year>2021</year>;<volume>163</volume>:<fpage>160</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbiomolbio.2021.01.004</pub-id>.<pub-id pub-id-type="pmid">33524442</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pillay</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tighe</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nelson</surname> &#160;<given-names>L</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>DNA replication vulnerabilities render ovarian cancer cells sensitive to poly(ADP-Ribose) glycohydrolase inhibitors</article-title>. <source>Cancer Cell</source>. <year>2019</year>;<volume>35</volume>:<fpage>519</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2019.02.004</pub-id>.<pub-id pub-id-type="pmid">30889383</pub-id><pub-id pub-id-type="pmcid">PMC6428690</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khan</surname> &#160;<given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Roos</surname> &#160;<given-names>WP</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname> &#160;<given-names>CR</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>DNA polymerase beta expression in head &amp; neck cancer modulates the poly(ADP-ribose)-mediated replication checkpoint</article-title>. <source>DNA Repair (Amst)</source>. <year>2025</year>;<volume>150</volume>:<fpage>103853</fpage>. <pub-id pub-id-type="doi">10.1016/j.dnarep.2025.103853</pub-id>.<pub-id pub-id-type="pmid">40472742</pub-id><pub-id pub-id-type="pmcid">PMC12281277</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coulson-Gilmer</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Morgan</surname> &#160;<given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Nelson</surname> &#160;<given-names>L</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models</article-title>. <source>J Exp Clin Cancer Res</source>. <year>2021</year>;<volume>40</volume>:<fpage>323</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-021-02124-0</pub-id>.<pub-id pub-id-type="pmid">34656146</pub-id><pub-id pub-id-type="pmcid">PMC8520217</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saville</surname> &#160;<given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Al-Rahahleh</surname> &#160;<given-names>RQ</given-names></string-name>, <string-name name-style="western"><surname>Siddiqui</surname> &#160;<given-names>AH</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity</article-title>. <source>DNA Repair (Amst)</source>. <year>2024</year>;<volume>140</volume>:<fpage>103700</fpage>. <pub-id pub-id-type="doi">10.1016/j.dnarep.2024.103700</pub-id>.<pub-id pub-id-type="pmid">38897003</pub-id><pub-id pub-id-type="pmcid">PMC11239280</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Acharya</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mani</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sah</surname> &#160;<given-names>N</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>CHK1 inhibitor induced PARylation by targeting PARG causes excessive replication and metabolic stress and overcomes chemoresistance in ovarian cancer</article-title>. <source>Cell Death Discov</source>. <year>2024</year>;<volume>10</volume>:<fpage>278</fpage>. <pub-id pub-id-type="doi">10.1038/s41420-024-02040-0</pub-id>.<pub-id pub-id-type="pmid">38862485</pub-id><pub-id pub-id-type="pmcid">PMC11166985</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hwang</surname> &#160;<given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bae</surname> &#160;<given-names>GU</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Protein arginine methyltransferases: promising targets for cancer therapy</article-title>. <source>Exp Mol Med</source>. <year>2021</year>;<volume>53</volume>:<fpage>788</fpage>&#8211;<lpage>808</lpage>. <pub-id pub-id-type="doi">10.1038/s12276-021-00613-y</pub-id>.<pub-id pub-id-type="pmid">34006904</pub-id><pub-id pub-id-type="pmcid">PMC8178397</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname> &#160;<given-names>J</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment</article-title>. <comment>bioRxiv</comment>, <pub-id pub-id-type="doi">10.1101/2024.05.21.595159</pub-id>, <comment>29 April 2025, preprint: not peer reviewed</comment>.</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>O&#8217;Brien</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Butticello</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname> &#160;<given-names>C</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer</article-title>. <source>BMC Cancer</source>. <year>2023</year>;<volume>23</volume>:<fpage>775</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-023-11260-z</pub-id>.<pub-id pub-id-type="pmid">37596538</pub-id><pub-id pub-id-type="pmcid">PMC10436459</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Dobrolecki</surname> &#160;<given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Sallas</surname> &#160;<given-names>C</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition</article-title>. <source>Cell Reports Medicine</source>. <year>2023</year>;<volume>4</volume>:<fpage>101326</fpage>. <pub-id pub-id-type="doi">10.1016/j.xcrm.2023.101326</pub-id>.<pub-id pub-id-type="pmid">38118413</pub-id><pub-id pub-id-type="pmcid">PMC10772459</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Giroud-Gerbetant</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Joffraud</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Giner</surname> &#160;<given-names>MP</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>A reduced form of nicotinamide riboside defines a new path for NAD<sup>+</sup> biosynthesis and acts as an orally bioavailable NAD<sup>+</sup> precursor</article-title>. <source>Molecular Metabolism</source>. <year>2019</year>;<volume>30</volume>:<fpage>192</fpage>&#8211;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmet.2019.09.013</pub-id>.<pub-id pub-id-type="pmid">31767171</pub-id><pub-id pub-id-type="pmcid">PMC6807296</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tang</surname> &#160;<given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Svilar</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Trivedi</surname> &#160;<given-names>RN</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>N-methylpurine DNA glycosylase and DNA polymerase &#946; modulate BER inhibitor potentiation of glioma cells to temozolomide</article-title>. <source>Neuro Oncol</source>. <year>2011</year>;<volume>13</volume>:<fpage>471</fpage>&#8211;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1093/neuonc/nor011</pub-id>.<pub-id pub-id-type="pmid">21377995</pub-id><pub-id pub-id-type="pmcid">PMC3093332</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guillemette</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Serra</surname> &#160;<given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4</article-title>. <source>Genes Dev</source>. <year>2015</year>;<volume>29</volume>:<fpage>489</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1101/gad.256214.114</pub-id>.<pub-id pub-id-type="pmid">25737278</pub-id><pub-id pub-id-type="pmcid">PMC4358401</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sakai</surname> &#160;<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Swisher</surname> &#160;<given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Jacquemont</surname> &#160;<given-names>C</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma</article-title>. <source>Cancer Res</source>. <year>2009</year>;<volume>69</volume>:<fpage>6381</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1178</pub-id>.<pub-id pub-id-type="pmid">19654294</pub-id><pub-id pub-id-type="pmcid">PMC2754824</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bodnar</surname> &#160;<given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Ouellette</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Frolkis</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Extension of life-span by introduction of telomerase into normal human cells</article-title>. <source>Science</source>. <year>1998</year>;<volume>279</volume>:<fpage>349</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1126/science.279.5349.349</pub-id>.<pub-id pub-id-type="pmid">9454332</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Slyskova</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sabatella</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ribeiro-Silva</surname> &#160;<given-names>C</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Base and nucleotide excision repair facilitate resolution of platinum drugs-induced transcription blockage</article-title>. <source>Nucleic Acids Res</source>. <year>2018</year>;<volume>46</volume>:<fpage>9537</fpage>&#8211;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky764</pub-id>.<pub-id pub-id-type="pmid">30137419</pub-id><pub-id pub-id-type="pmcid">PMC6182164</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fang</surname> &#160;<given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Inanc</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Schamus</surname> &#160;<given-names>S</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>HSP90 regulates DNA repair via the interaction between XRCC1 and DNA polymerase beta</article-title>. <source>Nat Commun</source>. <year>2014</year>;<volume>5</volume>:<fpage>5513</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms6513</pub-id>.<pub-id pub-id-type="pmid">25423885</pub-id><pub-id pub-id-type="pmcid">PMC4246423</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Desjardins</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname> &#160;<given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Allen</surname> &#160;<given-names>M</given-names></string-name></person-group>. <article-title>Microvolume protein concentration determination using the NanoDrop 2000c spectrophotometer</article-title>. <source>J Vis Exp</source>. <year>2009</year>;<fpage>e1610</fpage>. <pub-id pub-id-type="doi">10.3791/1610</pub-id>.<pub-id pub-id-type="pmcid">PMC3157846</pub-id><pub-id pub-id-type="pmid">19890248</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname> &#160;<given-names>X</given-names></string-name></person-group>. <article-title>Cell synchronization by double thymidine block</article-title>. <source>Bio Protoc</source>. <year>2018</year>;<volume>8</volume>:<fpage>e2994</fpage>. <pub-id pub-id-type="doi">10.21769/BioProtoc.2994</pub-id>.<pub-id pub-id-type="pmcid">PMC6156087</pub-id><pub-id pub-id-type="pmid">30263905</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname> &#160;<given-names>X</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Serum starvation induced cell cycle synchronization facilitates human somatic cells reprogramming</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>:<fpage>e28203</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0028203</pub-id>.<pub-id pub-id-type="pmid">22529890</pub-id><pub-id pub-id-type="pmcid">PMC3329488</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>VanArsdale</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Boshoff</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Arndt</surname> &#160;<given-names>KT</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment</article-title>. <source>Clin Cancer Res</source>. <year>2015</year>;<volume>21</volume>:<fpage>2905</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0816</pub-id>.<pub-id pub-id-type="pmid">25941111</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Inanc</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname> &#160;<given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Roos</surname> &#160;<given-names>WP</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>TRIP12&#8217;s role in the governance of DNA polymerase beta involvement in DNA damage response and repair</article-title>. <source>Nucleic Acids Res</source>. <year>2025</year>;<volume>53</volume>:<fpage>gkaf574</fpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaf574</pub-id>.<pub-id pub-id-type="pmid">40613707</pub-id><pub-id pub-id-type="pmcid">PMC12231584</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kessel</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cribbes</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bonasu</surname> &#160;<given-names>S</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Real-time apoptosis and viability high-throughput screening of 3D multicellular tumor spheroids using the Celigo image cytometer</article-title>. <source>SLAS Discovery</source>. <year>2018</year>;<volume>23</volume>:<fpage>202</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1177/2472555217731076</pub-id>.<pub-id pub-id-type="pmid">28915356</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cho</surname> &#160;<given-names>KF</given-names></string-name>, <string-name name-style="western"><surname>Branon</surname> &#160;<given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Udeshi</surname> &#160;<given-names>ND</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Proximity labeling in mammalian cells with TurboID and split-TurboID</article-title>. <source>Nat Protoc</source>. <year>2020</year>;<volume>15</volume>:<fpage>3971</fpage>&#8211;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1038/s41596-020-0399-0</pub-id>.<pub-id pub-id-type="pmid">33139955</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname> &#160;<given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Languino</surname> &#160;<given-names>LR</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Evaluation of drug combination effect using a Bliss independence dose-response surface model</article-title>. <source>Stat Biopharm Res</source>. <year>2018</year>;<volume>10</volume>:<fpage>112</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1080/19466315.2018.1437071</pub-id>.<pub-id pub-id-type="pmid">30881603</pub-id><pub-id pub-id-type="pmcid">PMC6415926</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kutuzov</surname> &#160;<given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Belousova</surname> &#160;<given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Kurgina</surname> &#160;<given-names>TA</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>The contribution of PARP1, PARP2 and poly(ADP-ribosyl)ation to base excision repair in the nucleosomal context</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>:<fpage>4849</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-84351-1</pub-id>.<pub-id pub-id-type="pmid">33649352</pub-id><pub-id pub-id-type="pmcid">PMC7921663</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guerrero&#160;Llobet</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bhattacharya</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Everts</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>An mRNA expression-based signature for oncogene-induced replication-stress</article-title>. <source>Oncogene</source>. <year>2022</year>;<volume>41</volume>:<fpage>1216</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1038/s41388-021-02162-0</pub-id>.<pub-id pub-id-type="pmid">35091678</pub-id><pub-id pub-id-type="pmcid">PMC7612401</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>da&#160;Costa</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chowdhury</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Shapiro</surname> &#160;<given-names>GI</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Targeting replication stress in cancer therapy</article-title>. <source>Nat Rev Drug Discov</source>. <year>2023</year>;<volume>22</volume>:<fpage>38</fpage>&#8211;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-022-00558-5</pub-id>.<pub-id pub-id-type="pmid">36202931</pub-id><pub-id pub-id-type="pmcid">PMC11132912</pub-id></mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weller</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rieger</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Grimmel</surname> &#160;<given-names>C</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses</article-title>. <source>Int J Cancer</source>. <year>1998</year>;<volume>79</volume>:<fpage>640</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1097-0215(19981218)79:6&amp;#x0003c;640::AID-IJC15&amp;#x0003e;3.0.CO;2-Z</pub-id>.<pub-id pub-id-type="pmid">9842975</pub-id></mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Flaman</surname> &#160;<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Frebourg</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Moreau</surname> &#160;<given-names>V</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>A simple p53 functional assay for screening cell lines, blood, and tumors</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>1995</year>;<volume>92</volume>:<fpage>3963</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.92.9.3963</pub-id>.<pub-id pub-id-type="pmid">7732013</pub-id><pub-id pub-id-type="pmcid">PMC42082</pub-id></mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ishii</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Maier</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Merlo</surname> &#160;<given-names>A</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines</article-title>. <source>Brain Pathol</source>. <year>1999</year>;<volume>9</volume>:<fpage>469</fpage>&#8211;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1111/j.1750-3639.1999.tb00536.x</pub-id>.<pub-id pub-id-type="pmid">10416987</pub-id><pub-id pub-id-type="pmcid">PMC8098486</pub-id></mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wischhusen</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Naumann</surname> &#160;<given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Ohgaki</surname> &#160;<given-names>H</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death</article-title>. <source>Oncogene</source>. <year>2003</year>;<volume>22</volume>:<fpage>8233</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1207198</pub-id>.<pub-id pub-id-type="pmid">14614447</pub-id></mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gorgoulis</surname> &#160;<given-names>VG</given-names></string-name>, <string-name name-style="western"><surname>Vassiliou</surname> &#160;<given-names>LV</given-names></string-name>, <string-name name-style="western"><surname>Karakaidos</surname> &#160;<given-names>P</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions</article-title>. <source>Nature</source>. <year>2005</year>;<volume>434</volume>:<fpage>907</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1038/nature03485</pub-id>.<pub-id pub-id-type="pmid">15829965</pub-id></mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guo</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname> &#160;<given-names>C</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>p53-driven replication stress in nucleoli of malignant epithelial ovarian cancer</article-title>. <source>Exp Cell Res</source>. <year>2022</year>;<volume>417</volume>:<fpage>113225</fpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2022.113225</pub-id>.<pub-id pub-id-type="pmid">35644414</pub-id></mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bryant</surname> &#160;<given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Petermann</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Schultz</surname> &#160;<given-names>N</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination</article-title>. <source>EMBO J</source>. <year>2009</year>;<volume>28</volume>:<fpage>2601</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2009.206</pub-id>.<pub-id pub-id-type="pmid">19629035</pub-id><pub-id pub-id-type="pmcid">PMC2738702</pub-id></mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname> &#160;<given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Kassab</surname> &#160;<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Dantzer</surname> &#160;<given-names>F</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PARP2 mediates branched poly ADP-ribosylation in response to DNA damage</article-title>. <source>Nat Commun</source>. <year>2018</year>;<volume>9</volume>:<fpage>3233</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-05588-5</pub-id>.<pub-id pub-id-type="pmid">30104678</pub-id><pub-id pub-id-type="pmcid">PMC6089979</pub-id></mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cho</surname> &#160;<given-names>KF</given-names></string-name>, <string-name name-style="western"><surname>Branon</surname> &#160;<given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Rajeev</surname> &#160;<given-names>S</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Split-TurboID enables contact-dependent proximity labeling in cells</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2020</year>;<volume>117</volume>:<fpage>12143</fpage>&#8211;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1919528117</pub-id>.<pub-id pub-id-type="pmid">32424107</pub-id><pub-id pub-id-type="pmcid">PMC7275672</pub-id></mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Demin</surname> &#160;<given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Hirota</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tsuda</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>XRCC1 prevents toxic PARP1 trapping during DNA base excision repair</article-title>. <source>Mol Cell</source>. <year>2021</year>;<volume>81</volume>:<fpage>3018</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2021.05.009</pub-id>.<pub-id pub-id-type="pmid">34102106</pub-id><pub-id pub-id-type="pmcid">PMC8294329</pub-id></mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Serrano-Benitez</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wells</surname> &#160;<given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Drummond-Clarke</surname> &#160;<given-names>L</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Unrepaired base excision repair intermediates in template DNA strands trigger replication fork collapse and PARP inhibitor sensitivity</article-title>. <source>EMBO J</source>. <year>2023</year>;<volume>42</volume>:<fpage>e113190</fpage>. <pub-id pub-id-type="doi">10.15252/embj.2022113190</pub-id>.<pub-id pub-id-type="pmid">37492888</pub-id><pub-id pub-id-type="pmcid">PMC10505916</pub-id></mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jackson</surname> &#160;<given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Moldovan</surname> &#160;<given-names>GL</given-names></string-name></person-group>. <article-title>Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment</article-title>. <source>NAR Cancer</source>. <year>2022</year>;<volume>4</volume>:<fpage>zcac042</fpage>. <pub-id pub-id-type="doi">10.1093/narcan/zcac042</pub-id>.<pub-id pub-id-type="pmid">36568963</pub-id><pub-id pub-id-type="pmcid">PMC9773381</pub-id></mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Murai</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname> &#160;<given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Das</surname> &#160;<given-names>BB</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Trapping of PARP1 and PARP2 by clinical PARP inhibitors</article-title>. <source>Cancer Res</source>. <year>2012</year>;<volume>72</volume>:<fpage>5588</fpage>&#8211;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2753</pub-id>.<pub-id pub-id-type="pmid">23118055</pub-id><pub-id pub-id-type="pmcid">PMC3528345</pub-id></mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Murai</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname> &#160;<given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Renaud</surname> &#160;<given-names>A</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib</article-title>. <source>Mol Cancer Ther</source>. <year>2014</year>;<volume>13</volume>:<fpage>433</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0803</pub-id>.<pub-id pub-id-type="pmid">24356813</pub-id><pub-id pub-id-type="pmcid">PMC3946062</pub-id></mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dunlop</surname> &#160;<given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Wallez</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname> &#160;<given-names>TI</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models</article-title>. <source>Br J Cancer</source>. <year>2020</year>;<volume>123</volume>:<fpage>1424</fpage>&#8211;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1038/s41416-020-1016-2</pub-id>.<pub-id pub-id-type="pmid">32741974</pub-id><pub-id pub-id-type="pmcid">PMC7591912</pub-id></mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carter</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hulse</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sivakumar</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PRMT5 inhibitors regulate DNA damage repair pathways in cancer cells and improve response to PARP inhibition and chemotherapies</article-title>. <source>Cancer Res Commun</source>. <year>2023</year>;<volume>3</volume>:<fpage>2233</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1158/2767-9764.CRC-23-0070</pub-id>.<pub-id pub-id-type="pmid">37861290</pub-id><pub-id pub-id-type="pmcid">PMC10627093</pub-id></mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bliss</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bouley</surname> &#160;<given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Petreaca</surname> &#160;<given-names>RC</given-names></string-name></person-group>. <article-title>Regulation of DNA repair gene expression by PRMT5</article-title>. <source>MicroPubl Biol</source>. <year>2025</year>;<volume>2025</volume>:<fpage>10.17912/micropub.biology.001631</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.17912/micropub.biology.001631</pub-id><pub-id pub-id-type="pmcid">PMC12305363</pub-id><pub-id pub-id-type="pmid">40735501</pub-id></mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Onishi</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jayamohan</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chowdhury</surname> &#160;<given-names>A</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PRMT5 inhibition sensitizes glioblastoma tumor models to temozolomide</article-title>. <source>Research Square</source>. <year>2025</year>. <pub-id pub-id-type="doi">10.21203/rs.3.rs-5936706/v1</pub-id>.</mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gillespie</surname> &#160;<given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Chiang</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Regan-Mochrie</surname> &#160;<given-names>GL</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells</article-title>. <source>Oncogene</source>. <year>2025</year>;<volume>44</volume>:<fpage>862</fpage>&#8211;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1038/s41388-024-03264-1</pub-id>.<pub-id pub-id-type="pmid">39695328</pub-id><pub-id pub-id-type="pmcid">PMC11932929</pub-id></mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pandya</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Vendetti</surname> &#160;<given-names>FP</given-names></string-name>, <string-name name-style="western"><surname>El-Ghoubaira</surname> &#160;<given-names>J</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Deoxyuridine-rich cytoplasmic DNA antagonizes STING-dependent innate immune responses and sensitizes resistant tumors to anti-PD-L1 therapy</article-title>. <comment>bioRxiv</comment>, <pub-id pub-id-type="doi">10.1101/2024.04.04.588079</pub-id>, <comment>5 April 2024, preprint: not peer reviewed</comment>.</mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saxena</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nabel</surname> &#160;<given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Seay</surname> &#160;<given-names>TW</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Unprocessed genomic uracil as a source of DNA replication stress in cancer cells</article-title>. <source>Mol Cell</source>. <year>2024</year>;<volume>84</volume>:<fpage>2036</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2024.04.004</pub-id>.<pub-id pub-id-type="pmid">38688279</pub-id><pub-id pub-id-type="pmcid">PMC11162326</pub-id></mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Vens</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sobol</surname> &#160;<given-names>RW</given-names></string-name></person-group>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Johnson</surname> &#160;<given-names>DE</given-names></string-name></person-group> (ed.), <source>Cell death signaling in cancer biology and treatment. X.-M. Yin and Z. Dong (Series eds.), Cell Death in Biology and Diseases</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer</publisher-name>, <year>2013</year>.</mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hoeijmakers</surname> &#160;<given-names>JH</given-names></string-name></person-group>. <article-title>Genome maintenance mechanisms for preventing cancer</article-title>. <source>Nature</source>. <year>2001</year>;<volume>411</volume>:<fpage>366</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1038/35077232</pub-id>.<pub-id pub-id-type="pmid">11357144</pub-id></mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Trucco</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Oliver</surname> &#160;<given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>de&#160;Murcia</surname> &#160;<given-names>G</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines</article-title>. <source>Nucleic Acids Res</source>. <year>1998</year>;<volume>26</volume>:<fpage>2644</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/nar/26.11.2644</pub-id>.<pub-id pub-id-type="pmid">9592149</pub-id><pub-id pub-id-type="pmcid">PMC147627</pub-id></mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ame</surname> &#160;<given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Rolli</surname> &#160;<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Schreiber</surname> &#160;<given-names>V</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase</article-title>. <source>J Biol Chem</source>. <year>1999</year>;<volume>274</volume>:<fpage>17860</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.25.17860</pub-id>.<pub-id pub-id-type="pmid">10364231</pub-id></mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zha</surname> &#160;<given-names>S</given-names></string-name></person-group>. <article-title>The dynamics and regulation of PARP1 and PARP2 in response to DNA damage and during replication</article-title>. <source>DNA Repair (Amst)</source>. <year>2024</year>;<volume>140</volume>:<fpage>103690</fpage>. <pub-id pub-id-type="doi">10.1016/j.dnarep.2024.103690</pub-id>.<pub-id pub-id-type="pmid">38823186</pub-id><pub-id pub-id-type="pmcid">PMC12217778</pub-id></mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hassa</surname> &#160;<given-names>PO</given-names></string-name>, <string-name name-style="western"><surname>Haenni</surname> &#160;<given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Elser</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?</article-title>. <source>Microbiol Mol Biol Rev</source>. <year>2006</year>;<volume>70</volume>:<fpage>789</fpage>&#8211;<lpage>829</lpage>. <pub-id pub-id-type="doi">10.1128/MMBR.00040-05</pub-id>.<pub-id pub-id-type="pmid">16959969</pub-id><pub-id pub-id-type="pmcid">PMC1594587</pub-id></mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vendetti</surname> &#160;<given-names>FP</given-names></string-name>, <string-name name-style="western"><surname>Pandya</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sclafani</surname> &#160;<given-names>CR</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Uracil-DNA glycosylase deficiency is associated with repressed tumor cell-intrinsic inflammatory signaling and altered sensitivity to exogenous interferons</article-title>. <comment>bioRxiv</comment>, <pub-id pub-id-type="doi">10.1101/2025.07.28.666960</pub-id>, <comment>1 August 2025, preprint: not peer reviewed</comment>.</mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Musiani</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yucel</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Vallette</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors</article-title>. <source>Mol Cell</source>. <year>2025</year>;<volume>85</volume>:<fpage>1072</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2025.01.031</pub-id>.<pub-id pub-id-type="pmid">40010343</pub-id></mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mosler</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Baymaz</surname> &#160;<given-names>HI</given-names></string-name>, <string-name name-style="western"><surname>Graf</surname> &#160;<given-names>JF</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PARP1 proximity proteomics reveals interaction partners at stressed replication forks</article-title>. <source>Nucleic Acids Res</source>. <year>2022</year>;<volume>50</volume>:<fpage>11600</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkac948</pub-id>.<pub-id pub-id-type="pmid">36350633</pub-id><pub-id pub-id-type="pmcid">PMC9723622</pub-id></mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Petropoulos</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Karamichali</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rossetti</surname> &#160;<given-names>GG</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Transcription-replication conflicts underlie sensitivity to PARP inhibitors</article-title>. <source>Nature</source>. <year>2024</year>;<volume>628</volume>:<fpage>433</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-024-07217-2</pub-id>.<pub-id pub-id-type="pmid">38509368</pub-id><pub-id pub-id-type="pmcid">PMC11006605</pub-id></mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Simbulan-Rosenthal</surname> &#160;<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Rosenthal</surname> &#160;<given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Boulares</surname> &#160;<given-names>AH</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Regulation of the expression or recruitment of components of the DNA synthesome by poly(ADP-ribose) polymerase</article-title>. <source>Biochemistry</source>. <year>1998</year>;<volume>37</volume>:<fpage>9363</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1021/bi9731089</pub-id>.<pub-id pub-id-type="pmid">9649317</pub-id></mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Simbulan-Rosenthal</surname> &#160;<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Rosenthal</surname> &#160;<given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Iyer</surname> &#160;<given-names>S</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Involvement of PARP and poly(ADP-ribosyl)ation in the early stages of apoptosis and DNA replication</article-title>. <source>Mol Cell Biochem</source>. <year>1999</year>;<volume>193</volume>:<fpage>137</fpage>&#8211;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1023/A:1006988832729</pub-id>.<pub-id pub-id-type="pmid">10331650</pub-id></mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dantzer</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Nasheuer</surname> &#160;<given-names>HP</given-names></string-name>, <string-name name-style="western"><surname>Vonesch</surname> &#160;<given-names>JL</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Functional association of poly(ADP-ribose) polymerase with DNA polymerase alpha-primase complex: a link between DNA strand break detection and DNA replication</article-title>. <source>Nucleic Acids Res</source>. <year>1998</year>;<volume>26</volume>:<fpage>1891</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/nar/26.8.1891</pub-id>.<pub-id pub-id-type="pmid">9518481</pub-id><pub-id pub-id-type="pmcid">PMC147507</pub-id></mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Berti</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ray&#160;Chaudhuri</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Thangavel</surname> &#160;<given-names>S</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition</article-title>. <source>Nat Struct Mol Biol</source>. <year>2013</year>;<volume>20</volume>:<fpage>347</fpage>&#8211;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb.2501</pub-id>.<pub-id pub-id-type="pmid">23396353</pub-id><pub-id pub-id-type="pmcid">PMC3897332</pub-id></mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xie</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mortusewicz</surname> &#160;<given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname> &#160;<given-names>HT</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Timeless interacts with PARP-1 to promote homologous recombination repair</article-title>. <source>Mol Cell</source>. <year>2015</year>;<volume>60</volume>:<fpage>163</fpage>&#8211;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2015.07.031</pub-id>.<pub-id pub-id-type="pmid">26344098</pub-id></mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schreiber</surname> &#160;<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Ame</surname> &#160;<given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Dolle</surname> &#160;<given-names>P</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1</article-title>. <source>J Biol Chem</source>. <year>2002</year>;<volume>277</volume>:<fpage>23028</fpage>&#8211;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M202390200</pub-id>.<pub-id pub-id-type="pmid">11948190</pub-id></mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koczor</surname> &#160;<given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Haider</surname> &#160;<given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Saville</surname> &#160;<given-names>KM</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Live cell detection of poly(ADP-Ribose) for use in genetic and genotoxic compound screens</article-title>. <source>Cancers</source>. <year>2022</year>;<volume>14</volume>:<fpage>3676</fpage>. <pub-id pub-id-type="doi">10.3390/cancers14153676</pub-id> .<pub-id pub-id-type="pmid">35954352</pub-id><pub-id pub-id-type="pmcid">PMC9367489</pub-id></mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Call</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tomkinson</surname> &#160;<given-names>AE</given-names></string-name></person-group>. <article-title>Joining of DNA breaks- interplay between DNA ligases and poly (ADP-ribose) polymerases</article-title>. <source>DNA Repair (Amst)</source>. <year>2025</year>;<volume>149</volume>:<fpage>103843</fpage>. <pub-id pub-id-type="doi">10.1016/j.dnarep.2025.103843</pub-id>.<pub-id pub-id-type="pmid">40347914</pub-id><pub-id pub-id-type="pmcid">PMC12218419</pub-id></mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kao</surname> &#160;<given-names>HI</given-names></string-name>, <string-name name-style="western"><surname>Bambara</surname> &#160;<given-names>RA</given-names></string-name></person-group>. <article-title>The protein components and mechanism of eukaryotic Okazaki fragment maturation</article-title>. <source>Crit Rev Biochem Mol Biol</source>. <year>2003</year>;<volume>38</volume>:<fpage>433</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1080/10409230390259382</pub-id>.<pub-id pub-id-type="pmid">14693726</pub-id></mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kumamoto</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nishiyama</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chiba</surname> &#160;<given-names>Y</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>HPF1-dependent PARP activation promotes LIG3-XRCC1-mediated backup pathway of Okazaki fragment ligation</article-title>. <source>Nucleic Acids Res</source>. <year>2021</year>;<volume>49</volume>:<fpage>5003</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkab269</pub-id>.<pub-id pub-id-type="pmid">33872376</pub-id><pub-id pub-id-type="pmcid">PMC8136790</pub-id></mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gottipati</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Vischioni</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Schultz</surname> &#160;<given-names>N</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells</article-title>. <source>Cancer Res</source>. <year>2010</year>;<volume>70</volume>:<fpage>5389</fpage>&#8211;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-4716</pub-id>.<pub-id pub-id-type="pmid">20551068</pub-id></mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koczor</surname> &#160;<given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Saville</surname> &#160;<given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Al-Rahahleh</surname> &#160;<given-names>RQ</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Quantitative analysis of nuclear poly(ADP-Ribose) dynamics in response to laser-induced DNA damage</article-title>. <source>Methods Mol Biol</source>. <year>2023</year>;<volume>2609</volume>:<fpage>43</fpage>&#8211;<lpage>59</lpage>.<pub-id pub-id-type="pmid">36515828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-0716-2891-1_3</pub-id><pub-id pub-id-type="pmcid">PMC9920208</pub-id></mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fugger</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bajrami</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Silva&#160;Dos&#160;Santos</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors</article-title>. <source>Science</source>. <year>2021</year>;<volume>372</volume>:<fpage>156</fpage>&#8211;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb4542</pub-id>.<pub-id pub-id-type="pmid">33833118</pub-id><pub-id pub-id-type="pmcid">PMC7610649</pub-id></mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Paes&#160;Dias</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tripathi</surname> &#160;<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>van&#160;der&#160;Heijden</surname> &#160;<given-names>I</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps</article-title>. <source>Mol Cell</source>. <year>2021</year>;<volume>81</volume>:<fpage>4692</fpage>&#8211;<lpage>708.e9</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2021.09.005</pub-id>.<pub-id pub-id-type="pmid">34555355</pub-id><pub-id pub-id-type="pmcid">PMC9098260</pub-id></mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Goel</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Venkatappa</surname> &#160;<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Krieger</surname> &#160;<given-names>KL</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced</article-title>. <source>NAR Cancer</source>. <year>2025</year>;<volume>7</volume>:<fpage>zcaf015</fpage>. <pub-id pub-id-type="doi">10.1093/narcan/zcaf015</pub-id>.<pub-id pub-id-type="pmid">40271221</pub-id><pub-id pub-id-type="pmcid">PMC12015684</pub-id></mixed-citation></ref><ref id="B147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Simpson</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ling</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jing</surname> &#160;<given-names>Y</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Mapping the genetic interaction network of PARP inhibitor response</article-title>. <comment>bioRxiv</comment>, <pub-id pub-id-type="doi">10.1101/2023.08.19.553986</pub-id>, <comment>20 August 2023, preprint: not peer reviewed</comment>.</mixed-citation></ref><ref id="B148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lazarides</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Engel</surname> &#160;<given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Meseonznik</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>CRISPR screens identify POLB as a synthetic lethal enhancer of PARP inhibition exclusively in BRCA-mutated tumors</article-title>. <source>Mol Cancer Ther</source>. <year>2025</year>;<volume>24</volume>:<fpage>1466</fpage>&#8211;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-24-0822</pub-id>.<pub-id pub-id-type="pmid">40326293</pub-id></mixed-citation></ref><ref id="B149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koh</surname> &#160;<given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Lawler</surname> &#160;<given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Poitras</surname> &#160;<given-names>MF</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2004</year>;<volume>101</volume>:<fpage>17699</fpage>&#8211;<lpage>704</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0406182101</pub-id>.<pub-id pub-id-type="pmid">15591342</pub-id><pub-id pub-id-type="pmcid">PMC539714</pub-id></mixed-citation></ref><ref id="B150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nie</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>DePARylation is critical for S phase progression and cell survival</article-title>. <source>eLife</source>. <year>2024</year>;<volume>12</volume>:<fpage>RP89303</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.89303</pub-id>.<pub-id pub-id-type="pmid">38578205</pub-id><pub-id pub-id-type="pmcid">PMC10997334</pub-id></mixed-citation></ref><ref id="B151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tentori</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Leonetti</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Scarsella</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide</article-title>. <source>Eur J Cancer</source>. <year>2005</year>;<volume>41</volume>:<fpage>2948</fpage>&#8211;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2005.08.027</pub-id>.<pub-id pub-id-type="pmid">16288862</pub-id></mixed-citation></ref><ref id="B152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fathers</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Drayton</surname> &#160;<given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Solovieva</surname> &#160;<given-names>S</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells</article-title>. <source>Cell Cycle</source>. <year>2012</year>;<volume>11</volume>:<fpage>990</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.4161/cc.11.5.19482</pub-id>.<pub-id pub-id-type="pmid">22333589</pub-id></mixed-citation></ref><ref id="B153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Andronikou</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Burdova</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Dibitetto</surname> &#160;<given-names>D</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair</article-title>. <source>EMBO J</source>. <year>2024</year>;<volume>43</volume>:<fpage>1015</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1038/s44318-024-00043-2</pub-id>.<pub-id pub-id-type="pmid">38360994</pub-id><pub-id pub-id-type="pmcid">PMC10943112</pub-id></mixed-citation></ref><ref id="B154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sugitani</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Vendetti</surname> &#160;<given-names>FP</given-names></string-name>, <string-name name-style="western"><surname>Cipriano</surname> &#160;<given-names>AJ</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-&#945;/&#946; expression</article-title>. <source>Cell Rep</source>. <year>2022</year>;<volume>40</volume>:<fpage>111371</fpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2022.111371</pub-id>.<pub-id pub-id-type="pmid">36130512</pub-id><pub-id pub-id-type="pmcid">PMC9646445</pub-id></mixed-citation></ref><ref id="B155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Randolph</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hyder</surname> &#160;<given-names>U</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Orso</surname> &#160;<given-names>I</given-names></string-name></person-group>. <article-title>KAP1/TRIM28: transcriptional activator and/or repressor of viral and cellular programs?</article-title>. <source>Front Cell Infect Microbiol</source>. <year>2022</year>;<volume>12</volume>:<fpage>834636</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2022.834636</pub-id>.<pub-id pub-id-type="pmid">35281453</pub-id><pub-id pub-id-type="pmcid">PMC8904932</pub-id></mixed-citation></ref><ref id="B156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blasius</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Forment</surname> &#160;<given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Thakkar</surname> &#160;<given-names>N</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>A phospho-proteomic screen identifies substrates of the checkpoint kinase Chk1</article-title>. <source>Genome Biol</source>. <year>2011</year>;<volume>12</volume>:<fpage>R78</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2011-12-8-r78</pub-id>.<pub-id pub-id-type="pmid">21851590</pub-id><pub-id pub-id-type="pmcid">PMC3245618</pub-id></mixed-citation></ref><ref id="B157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ziv</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bielopolski</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Galanty</surname> &#160;<given-names>Y</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway</article-title>. <source>Nat Cell Biol</source>. <year>2006</year>;<volume>8</volume>:<fpage>870</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/ncb1446</pub-id>.<pub-id pub-id-type="pmid">16862143</pub-id></mixed-citation></ref><ref id="B158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McCabe</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname> &#160;<given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Lord</surname> &#160;<given-names>CJ</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition</article-title>. <source>Cancer Res</source>. <year>2006</year>;<volume>66</volume>:<fpage>8109</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0140</pub-id>.<pub-id pub-id-type="pmid">16912188</pub-id></mixed-citation></ref><ref id="B159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mitchell</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Park</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Eulitt</surname> &#160;<given-names>P</given-names></string-name> &#160;<etal>et al.</etal></person-group> &#160;<article-title>Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells</article-title>. <source>Mol Pharmacol</source>. <year>2010</year>;<volume>78</volume>:<fpage>909</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1124/mol.110.067199</pub-id>.<pub-id pub-id-type="pmid">20696794</pub-id><pub-id pub-id-type="pmcid">PMC2981366</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>